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Introduction
Several committees were established by the
National Association of Physicians for the
Environment (NAPE) to investigate and report
on various topics at the National Leadership
Conference on Biomedical Research and the
Environment held 1–2 November 1999 at the
National Institutes of Health (NIH) in
Bethesda, Maryland. This is the report of the
Committee on Minimization and Management
of Wastes from Biomedical Research. 
Background
Waste management issues were among the
core concerns addressed by the conference. It
is anticipated that the budget of NIH will
double in the next 5 years, and similar
increases in for-profit research are expected.
John E. Porter, Chairman of the House
Subcommittee on Labor, Health and Human
Services, and Education Appropriations, the
conveners of the conference, and others have
raised concerns that the boom in research
activities associated with this funding will
have the potential to increase generation of
wastes that can be very damaging to the
environment (1,2). The charge of the
committee on Minimization and Management
of Wastes from Biomedical Research was to
address these concerns.
Committee Topics, Organization,
Objectives, and Methods
Topics investigated. The scope of work
assigned to the committee described in the
conference agenda (3) was extensive. Major
tasks included the following: characterization
of the various types of wastes generated by
biomedical research facilities; review of cur-
rent waste management methods; evaluation
of the potential for adverse impacts from
waste generation on both the environment
and the research mission; reporting on
strategies for reducing these impacts; and pro-
viding examples of best practices for pollution
prevention (source reduction or waste avoid-
ance) and waste minimization (volume and
toxicity reduction) at research facilities
Committee composition and organization.
The chairman of the committee was
appointed by NAPE. The committee com-
prised seven subcommittees, each with a
chairperson appointed by the committee
chairman. Six subcommittees focused on the
various types of wastes generated by research
facilities (biohazardous and regulated medical
wastes, chemical wastes, pharmaceutical
wastes, radioactive wastes, multihazardous
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wastes, and solid wastes and recycling), and
one subcommittee was assigned to review
training issues relating to waste management.
Subcommittee chairs were responsible for col-
lecting information, presenting conference
workshops, and preparing sections of this
report applicable to their subject area.
Conference registrants who expressed an
interest in waste issues were invited to serve
on the committee, and additional members
were recruited by the subcommittee chairs.
Members were afﬁliated with a diverse spec-
trum of organizations, including academia,
professional societies, pharmaceutical
research laboratories, waste management
industry, environmental organizations, NIH,
U.S. Environmental Protection Agency
(EPA), and state environmental agencies. All
chairs and members served as unpaid volun-
teers, and no funds were received in support
of the committee.
Sources of information and methods. The
information in this report was compiled by
the committee chairman and based largely on
data provided by the members of the com-
mittee, published references, and input from
attendees at the conference. Drafts of all sub-
committee reports and the final, full report
were distributed to the members for review.
This report should be considered the consen-
sus ﬁndings of the committee.
Characterization of Wastes from
Biomedical Research
General categories of wastes. Biomedical
research facilities generate a complex array of
wastes, which may be broadly grouped into
two categories: biomedical research wastes
(BRW) that are direct products of research
activities, and other conventional wastes
from research support operations such as
facility construction, operation, mainte-
nance, and demolition, food service, and
administrative functions. 
With some exceptions, conventional
wastes from biomedical research facilities are
similar to or indistinguishable from wastes
generated by other sources. Minimization
strategies for these wastes and the issues sur-
rounding their recycling and management are
well established in the literature and are not
covered in detail here. This report focuses on
BRW. However, a boom in construction of
new and renovated facilities will undoubtedly
follow the anticipated increases in public and
private funding for research. This has the
potential to concomitantly increase genera-
tion of conventional wastes, especially con-
struction and demolition wastes. These wastes
must be appropriately managed and recycled
or disposed of in a manner protective of the
environment.
Characteristics of wastes from biomedical
research.  Major sources of BRW are
laboratories, patient diagnosis and treatment,
and husbandry of laboratory animals. These
wastes, especially those from laboratory
activities, may differ from wastes from other
sources in several respects, and these differ-
ences may significantly affect how BRW is
classiﬁed, regulated, and disposed.
Manufacturing facilities and most other
large industrial operations tend to generate
wastes that are few in number, recurring, and
in relatively large volumes. This contrasts
with biomedical facilities, which typically
generate hundreds, sometimes thousands of
different wastes, usually in small volumes,
and often as the result of a one-time experi-
ment or protocol. These properties signifi-
cantly increase the complexity of BRW
management and reduce the economies of
scale. Unit costs of analyzing, processing,
record keeping, shipping, treating, and dis-
posing of BRW may be orders of magnitude
higher than for conventional wastes.
Biomedical research wastes may contain
multiple types of hazardous materials—com-
binations of toxic chemicals, radioactive
materials, and biohazardous agents. Selecting
treatment methods for these multihazardous
wastes and determining the most appropriate
sequence of treatment procedures is often a
complicated and problematic task. The pres-
ence of multiple types of hazardous materials
may also reduce or eliminate access to dis-
posal facilities, as these facilities can usually
process only a single type of waste.
The hazardous properties of many materials
used in research may not be known or are
described incompletely.
Biomedical research wastes, particularly
those from medical procedures, may have aes-
thetically objectionable characteristics affect-
ing how they must be managed. For example,
pathological wastes may have to be processed
in a manner that renders them unrecogniz-
able before they are disposed.
Special security requirements may apply
to handling and destruction of wastes that
contain confidential or protected informa-
tion and items that must be protected from
diversion to unauthorized uses. Examples of
such wastes include a) medical records, clini-
cal specimens, and other items labeled with
patient identification information; b)
research data and samples; and c) controlled
substances.
Quantities of wastes generated by
biomedical research. Current and well-
documented data on the amounts of wastes
generated by biomedical research activities
and national trends for these wastes are
scant. There are no routine surveys or
national reporting requirements for wastes
except for certain hazardous wastes regulated
by EPA. Hazardous waste-generation data
must be reported by facilities on a biannual
basis (4). Even for these wastes, it is difﬁcult
to determine the amount generated by bio-
medical research activities. Generation data
from generator reports are aggregated by stan-
dard industry classiﬁcation (SIC) codes. There
is no applicable SIC code for facilities that only
conduct biomedical research. At other facili-
ties, such as hospitals and universities that have
applicable codes, research wastes are mingled
with wastes from nonresearch sources. Finally,
many research activities are not conducted in
facilities; they occur in clinics, doctors’ ofﬁces,
and homes. For example, investigational drugs
or experimental devices may be given to
patients for use at home. Wastes from these
activities are disposed of by patients and others
at off-site locations and are not reported by the
originating research facility.
Although data are limited, it is possible to
estimate the magnitude of contributions from
biomedical research to the total amounts of
various types of regulated BRW generated in
the United States. Most research activities are
conducted in laboratories, hospitals, and aca-
demic institutions, and some waste genera-
tion survey data are available for these types
of generators. Although biomedical research
accounts for a small fraction of the aggregate
amounts of wastes reported by these genera-
tors, the data can be used to develop upper
estimates for various types of BRW.
Hazardous wastes. A survey conducted in
the late 1980s reported that less than 1% of
the hazardous wastes generated annually in
the United States came from the 30,000 edu-
cational institutions in existence at the time
(5). All laboratories combined, regardless of
function, generated less than 1/100 of 1% of
the nation’s hazardous waste (6).
Medical wastes. Laboratories contribute
3.3% and hospitals 77.1% of the total
amount of regulated medical wastes in the
United States (7). There are no reliable data
on medical waste generation from nonhospi-
tal health care sites (8). 
Radioactive wastes. Medical and research
facilities combined account for less than 5%
of the total volume of low-level radioactive
wastes generated in the United States (9).
Multihazardous wastes. Data are not avail-
able on generation of multihazardous wastes
except for regulated mixed wastes (radioactive
hazardous wastes). A national survey of genera-
tors of mixed waste reported that medical facil-
ities accounted for 564 m3, or 20.4%, of the
total reported generation of 2,765 m3 (10). 
From this limited information it is appar-
ent that biomedical research facilities account
for a very small to negligible fraction of the
total amounts of regulated wastes generated
in the United States. It should be understood
that the potential impacts of these wastes are
only partially determined by the amounts of
waste generated. The concentrations and
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environmental toxicology of hazardous
constituents in the waste, and the protective-
ness of methods used to treat and dispose of
the wastes may be larger determinants of
potential risks to the environment. These fac-
tors are reviewed later in this report.
Incentives for Improving Waste
Minimization and Management
There are strong incentives for improving
waste minimization and management pro-
grams in research facilities.
Reduction of institutional health and
safety hazards. The potential for exposures of
employees, patients, visitors, and waste man-
agement personnel to safety, ﬁre, and health
hazards associated with wastes is reduced.
Greater emphasis on source reduction (waste
avoidance) practices eliminates or reduces
waste generation and its hazards. Other mini-
mization practices reduce the volume and
toxicity of unavoidable wastes, and improve-
ments in transportation, storage, treatment,
and disposal of wastes reduce hazards by
ensuring containment of hazardous materials
and prompt removal of these materials from
the workplace.
Environmental protection. Wastes and
pollutants from research activities can directly
cause damage to the environment if released
in an uncontrolled manner or treated
improperly before disposal, or if treated
wastes are discharged into inappropriate envi-
ronmental media. Even if wastes are managed
properly, secondary wastes and pollutants
from their transportation, recycling, and
treatment are an inevitable consequence of
waste generation. These impacts can only be
prevented by elimination of wastes at the
source—pollution prevention.
Regulatory compliance. Disposal of
hazardous, radioactive, and medical wastes is
an intensely regulated activity. A complex
framework of Federal, state, regional, and local
laws, licenses, and permits govern virtually all
aspects of waste management from “cradle to
grave,” including labeling and identiﬁcation,
on-site storage and management, transporta-
tion, treatment, and disposal. Severe penalties
may be levied against both facilities and indi-
viduals for noncompliance. These may include
criminal or civil actions leading to restrictions
or revocations of facility operating permits,
fines, and imprisonment. Academic and
research facilities have recently been the focus
of enhanced enforcement efforts by EPA and
state agencies (11,12).
Laws providing general mandates for pol-
lution prevention and waste minimization
have also been enacted. These include the
Solid Waste Management Act of 1965 (13),
as amended by the Resource Conservation
and Recovery Act of 1976 (RCRA) (14), and
the Pollution Prevention Act of 1990 (15)
(PPA). Enabling Federal regulations setting
forth specific source reduction and mini-
mization requirements have not been estab-
lished for most types of wastes. RCRA
regulations requiring generators to reduce the
volume and toxicity of hazardous (chemical)
wastes is the major exception. Biomedical
research programs conducted by Federal
agencies are also subject to several Executive
orders requiring agencies to establish pollu-
tion prevention programs, set waste reduc-
tion goals, and use products made from
recycled materials. The most comprehensive
of these is Executive Order 13148 of April
21, 2000, titled Greening the Government
Through Environmental Leadership (16).
Liability avoidance. Significant short-
term and long-term liability is associated with
generation of all types of wastes, particularly
hazardous and radioactive wastes. Liability for
costs relating to remediation of environmen-
tal damage from these wastes (environmental
impairment liability) may be catastrophic.
Generators never escape liability for their
wastes. Even if wastes are managed and dis-
posed of in accordance with all regulatory
requirements by fully licensed and permitted
contractors, the generator retains liability and
may be responsible for damages found years
later. Liability is also joint and several.
Generators responsible for a relativity small
amount of waste at a contaminated site may
incur liability for clean up of a disproportion-
ately large fraction of the total costs. 
Disposal cost avoidance. Costs associated
with management and disposal of wastes may
consume a significant amount of research
funds. For many facilities, avoidance of these
costs provides ample justification for imple-
mentation of comprehensive source reduction
and minimization programs. Unit costs for
disposal of BRW are often much higher than
for conventional wastes, and these costs may
differ by orders of magnitude among the vari-
ous types of wastes. Typical treatment and dis-
posal costs have not been published. Examples
of estimated unit costs reported to the com-
mittee by NIH and other committee members
are presented in Table 1 to illustrate the mag-
nitude of costs that may be encountered and
differences among different types of wastes.
(Actual costs incurred by other facilities may
vary considerably from these estimates and
will be affected by many factors such as con-
centrations of hazardous constituents in the
waste, management methods, volume of
waste, contractors and disposal facilities used,
and location of the research facility).
Community relations. Waste manage-
ment issues are a major source of public con-
cern. Misinformation on waste management
can create misperceptions about research
facility operations. Facilities with open, well-
managed pollution prevention and waste
management programs help to maintain
public conﬁdence in the research program.
Value of laboratory wastes as a teaching
tool. Although the amounts of wastes and
pollutants generated by individual research
procedures are usually small, they provide an
excellent opportunity for investigators to
learn, practice, and teach the principles of
environmental stewardship in the laboratory.
These lessons can then be applied to ensure
that the products of biomedical research and
development—medical procedures, drugs,
and supplies—will not become major sources
of pollution and wastes, as they are subse-
quently used on a large scale in the health
care system. 
General Strategies for Pollution
Prevention and Waste Minimization
The PPA established as a national policy a
hierarchy of waste minimization and man-
agement approaches with preference for
those providing the greatest protection of the
environment:
The Congress hereby declares it to be the
national policy of the United States that
pollution should be prevented or reduced
at the source whenever feasible; pollution
that cannot be prevented should be recy-
cled in an environmentally safe manner
whenever feasible; pollution that cannot be
prevented or recycled should be treated in
an environmentally safe manner whenever
feasible; and disposal or other release into
the environment should be employed only
as a last resort and should be conducted in
an environmentally safe manner. (15)
The PPA provides guidance for selecting
general approaches to pollution prevention
and waste minimization solely on the basis of
environmental considerations. For research
facilities, it is of paramount importance to
ensure that the approaches used will not have
adverse effects on patients, laboratory
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Table 1. Typical unit costs for treatment and disposal of
various types of wastes generated by biomedical
research facilities.
Unit cost 
Type of waste (U.S. dollars)a Units
Solid wastes, nonhazardous 0.10 kg
Medical wastes, regulated 1.00 kg
Bulk solvents, drum lots 0.50–1.50 L
Liquid scintillation counting vials 1.70–2.50 kg
Chemicals shipped in lab packs 9.00–30.00 kg
Chemicals, highly reactive 25.00–> 350.00 kg
Low-level radioactive wastes,  20.00–50.00 kg
solid
Animal carcasses, radioactive 35.00–50.00 kg
Low-level radioactive mixed  5.00–> 250.00 kg
wastes, liquid
High-3H mixed wastes, liquid 8,000,000– L
33,000,000
aThese are only costs of waste treatment and disposal; other
costs associated with waste collection, analysis, accounting,
packaging, storage, processing, and shipping are not included.
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animals, and scientific productivity. Cost
effectiveness and feasibility should also be
considered. With these considerations in
mind, many facilities have found that many
of the same pollution prevention and waste
minimization strategies used in industry can
be successfully applied to research operations.
These strategies include a) better procure-
ment management, especially avoiding
overordering of hazardous materials; b) sub-
stitution of hazardous materials with less
hazardous or nonhazardous materials;
c) reducing the scale of experiments and pro-
tocols to the minimum size necessary to
achieve research objectives; d) redistribution,
reuse, and recycling of supplies and reagents;
and e) improved waste segregation to maxi-
mize recovery of materials and treatability of
wastes; and f ) ensuring that all staff mem-
bers are aware of the need to minimize
wastes and are trained on minimization
methods applicable to job duties.
Ultimately, the best ideas for pollution
prevention often originate from within the
research community itself. Investigators are
intimately familiar with the research proce-
dures and objectives of experimental proto-
cols and can evaluate the trade-offs associated
with changes in procedures necessary to
achieve pollution prevention objectives.
Increasing the awareness of researchers of the
problems associated with management of
BRW is the first step. The innovations in
research methods that follow can have a
long-lasting effect on laboratory operations
and the quantity of wastes generated from
these activities.
The EPA Waste Minimization Oppor-
tunity Assessment Manual (17) provides fur-
ther guidance on selecting waste minimization
methods. Other comprehensive references on
waste minimization and management with
emphasis on laboratories and medical facilities
are available (18–21). Examples of best prac-
tices for waste minimization and management
in biomedical research facilities are presented
in the subcommittee reports that follow.
Subcommittee Reports
Subcommittee on
Biohazardous and Regulated
Medical Wastes
Classiﬁcation and Deﬁnitions
Research facilities often generate significant
quantities of wastes containing materials of
biological origin. These biological wastes may
be subject to special management require-
ments under Federal, state, or local regula-
tions if they contain, are contaminated with,
or perceived to be contaminated with a) bio-
hazardous (infectious) agents; b) blood or
other body fluids; c) toxins; d) pathological
wastes—solid human or animal tissues;
e) genetically altered materials or organisms;
and f ) needles, scalpels, syringes, and other
sharp objects that present physical hazards
and may be contaminated with biohazardous
agents. Biological wastes subject to these
requirements are referred to in this report as
regulated medical wastes (RMW). 
Because biohazardous waste is regulated
by various agencies and accrediting organiza-
tions with different authorities, policies, and
concerns, there is not a singular method by
which biomedical research facilities can deﬁne
it. Biohazardous waste is usually considered
by the scientiﬁc community to be a waste that
could, in a susceptible host, cause infection
that may develop into a disease—a recogniz-
able departure from normal. However, the
public often perceives a waste to be biohaz-
ardous on the basis of its source and appear-
ance. Waste appearing to originate from a
hospital, clinic, or biomedical research labora-
tory is often assumed biohazardous, even if,
scientifically, potentially infectious microor-
ganisms or toxins are not present.
The regulated community is often frus-
trated by the lack of consistency in deﬁnitions
of RMW. Several attempts have been made
to create a deﬁnition that can be used by all
interested parties. The most recent of these
was described in a U.S. Department of
Transportation (DOT) advance notice of
proposed rulemaking (22). Here DOT pro-
posed to define infectious substances (and
wastes) on the basis of risk groups (RGs) of
the World Health Organization (WHO).
These RGs characterize infectious substances
on the basis of the pathogenicity of the
organism, mode and relative ease of disease
transmission, risk of infection to individuals
and community, and reversibility of the dis-
ease through known and effective preventa-
tive agents and treatment.
To ensure proper characterization and
management of RMW, research facilities
should review Federal, state, and local regu-
lations for current definitions and require-
ments. See Wagner (23) for a more
complete discussion of RMW definitions
and related issues.
Characterization of RMW 
from Biomedical Research
The composition of RMW generated by
biomedical research facilities is generally simi-
lar to that generated by hospitals and other
healthcare installations. However, wastes
from some research facilities may contain
additional constituents not commonly found
in wastes from healthcare.
Carcasses, bedding, and other wastes from
the care and use of laboratory animals.
Carcasses are usually incinerated even if they
are not biohazardous or regulated as RMW.
Genetically altered materials and
organisms. These are usually managed in the
same manner as RMW. The recommended
inactivation and disposal methods vary
depending on the biosafety level assigned to
each material (24).
Other hazardous contaminants (chemicals,
drugs, and radioactive materials). If these are
present, the wastes must be managed as mul-
tihazardous wastes. 
The amount of RMW generated by bio-
medical research activities depends on several
factors, including the nature of the research,
the type and size of the facility, waste deﬁni-
tions used, and the effectiveness of minimiza-
tion efforts. Typical biomedical research
laboratories usually generate up to 20 kg of
biohazardous wastes per day; a clinical micro-
biology laboratory may generate hundreds of
kilograms. A large, thousand bed, tertiary care
hospital may generate up to 6 tons of biohaz-
ardous waste per day.
Assessment of Potential Environmental
Impacts
Direct impacts—biohazards. After extensive
studies conducted under provisions of the
Medical Waste Tracking Act of 1988 (25),
EPA concluded that the disease-causing
potential of medical waste is greatest at the
point of generation and naturally tapers off
after that point, thus presenting more of an
occupational concern than a generalized envi-
ronmental concern. Risk to the public of dis-
ease caused by exposure to medical waste is
likely to be much lower than risk for the
occupationally exposed individual (26). There
is no scientific evidence of disease transmis-
sion from medical wastes via environmental
media (8,27). Several factors limit the poten-
tial for disease transmission from biomedical
research facility wastes:
Most facilities do not handle high-risk
organisms. The Centers for Disease Control
and Prevention and NIH classify infectious
agents and laboratory activities involving
manipulation of biohazardous agents into
four biosafety levels (BSLs) (28). The BSLs
range from 1 to 4, with BSL 1 representing
the agents that pose the lowest risk of disease
transmission. This classification system is
widely accepted by regulatory bodies in the
United States, although recent debate at the
Federal level opened the door to using the
RGs of the WHO. The WHO RGs also
range from 1 to 4. RG 1 represents microor-
ganisms that are unlikely to cause human or
animal disease. RG 4 is used for pathogens
that usually cause serious disease that can be
readily transmitted and for which effective
treatment and preventative measures are not
usually available. Regardless of which risk-
based system is used, few biomedical research
facilities handle agents more hazardous than
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those typically found in medical wastes from
hospitals and other healthcare facilities (BSLs
1 and 2; RGs 1 and 2). Research with agents
classiﬁed as BSLs 2, 3, and 4 (RG 2, 3, and
4) is performed only in facilities designed,
operated, and permitted in a manner that
assures containment of the agents. Guidance
on the design and operation of infectious
waste management systems for such facilities
is available (29).
Cultures are inactivated before disposal.
Biohazardous waste with the greatest poten-
tial for causing disease in a susceptible host is
waste that contains cultures of pathogenic
microorganisms. Although other biohaz-
ardous forms of RMW may transmit disease,
the risk is considerably less. Microbiologists
generally decontaminate cultures of microor-
ganisms before discarding the treated material
into the RMW stream. Operational guide-
lines strongly recommend all wastes from
BSLs 2, 3, and 4 be inactivated before they
are disposed (28).
Concentrations of potentially infectious
agents in RMW are relatively low. The concen-
trations of human pathogens in medical waste
are lower than those in household wastes, and
these wastes pose nominal risks (30,31). 
Infectious agents routinely encountered in
RMW are not resilient under environmental
conditions. Many human pathogens found in
medical waste tend to inactivate rapidly when
released into the general environment, and
conditions in landfills do not favor their
growth or survival (31).
Indirect impacts from waste treatment
operations. Incineration and other medical
waste treatment processes can generate sec-
ondary wastes and pollutants if treatment
facilities are not designed, constructed, and
operated properly. These pollutants may have
adverse environmental impacts.
Air emissions. Polychlorinated dioxins and
dibenzofurans, toxic heavy metals (mercury
and cadmium), and corrosive gases (hydrogen
chloride) may be produced by medical waste
incinerators (32). Varying levels of pollutants
may also be emitted from alternative (non-
incineration) treatment processes, depending
on the method used for pathogen inactivation
and the type of waste being treated. Whether
these pollutants are released into the environ-
ment or contained depends on a number of
operational factors and the level of technolog-
ical advancement inherent in the treatment
system.
Wastewater effluents. Another potential
source of indirect impacts is the use of chemi-
cal disinfectants that may be regulated as
toxic pollutants under the Federal Water
Pollution Control Act (Clean Water Act)
(33), and state and local pollution control
laws. Phenolic disinfectants are of particular
concern because they may disrupt wastewater
treatment processes or result in discharges of
toxic effluents. Many publicly owned treat-
ment works (POTWs) have set allowable
wastewater concentration limits for phenolic
compounds at very low levels, precluding dis-
posal of wastes containing these disinfectants
via the sewerage system. 
Planning for Improved RMW Source
Reduction and Management Strategies
Disposal of RMW continues to be a costly
component of healthcare and biomedical
research. Consequently, many facilities have
developed comprehensive plans for source
reduction and improved management of
medical wastes. Designing such a plan
requires a multidisciplinary team. The team
must be capable of a) conducting an environ-
mental, health, and safety audit; b) using sur-
vey methods to collect baseline data on the
quantities and types of waste generated by the
facility; c) developing and implementing a
system to both identify source reduction
action items and track progress; and d) ensur-
ing staff training. To be cost effective, the
extent of the program must be tailored to ﬁt
the size of the facility and the total amount of
waste generated (34,35).
Early involvement of employees in the
planning process and continuous training of
employees are critical elements of successful
medical waste minimization programs.
Employees must be fully aware of the con-
tents of the facility’s waste management plan,
including regulations that apply, how to seg-
regate the types of waste the facility generates,
how to choose environmentally preferable
materials, and how to properly dispose of
unavoidable wastes. There also should be a
feedback system such that a facility can
detect, investigate, and correct deficiencies
and problems with the plan itself.
Source Reduction Methods
Improved segregation of wastes. Improving
segregation of wastes is probably the strategy
most widely and successfully used by health-
care institutions to reduce generation of
RMW. The application of this strategy in
research facilities is feasible but sometimes
more difﬁcult.
Segregation is easiest to implement in
areas where waste streams are recurring and
well characterized. This is not the situation in
research facilities, where unique, small-quan-
tity waste streams are often generated from
one-time experiments or special projects.
Despite this difficulty, separating medical
waste streams into infectious/noninfectious
waste or regulated/nonregulated categories
should be possible. If large amounts of waste
are generated, additional segregation of wastes
treated on-site from those shipped off-site
may greatly diminish facility expenses.
Compliance with segregation requirements
is improved by placing containers of the
appropriate size and type in convenient loca-
tions. In biomedical facilities, the large num-
ber of potential segregation categories,
limited space availability for collection con-
tainers, and logistical problems associated
with collecting many small waste streams
may limit this practice. 
Other methods. Many other source reduc-
tion methods have been successfully used by
healthcare facilities to reduce generation of
medical wastes; these may be applicable to
biomedical research facilities as well.
Examples include a) reprocessing and reuse of
disposable medical supplies (36); b) use or
donation of unused or reprocessed medical
supplies (37,38); c) reduced use of disposables
and elimination of excess packaging; and d)
use of dissolvable gowns and other medical
supplies (39).
Some plastics and other materials in bio-
hazardous waste may be recycled in a cost-
effective and environmentally protective
manner. The level of recycling for biohaz-
ardous wastes is not fully known but is proba-
bly low. Recycling options are limited by
factors such as regulatory restrictions, con-
cerns over the efﬁcacy of treatment for infec-
tious agents that may have contaminated the
material to be recycled, quality control issues,
public perceptions, and the limited markets
for materials recovered from these wastes.
Costs associated with sorting recyclable mate-
rials and shipping and processing them for
recovery further impact the cost effectiveness
of recycling.
Trends in research methodology also
affect the reuse and recycling of decontami-
nated wastes from research laboratories. For
example, up until the 1950s, bacteriologists
used reusable glass petri dishes. They then
switched to disposable plastics. Likewise, in
the late 1970s, microbiologists switched to
using plastic pipettes instead of glass. The use
of glass in the laboratory is not likely to
change because of the labor costs involved
with cleaning and sterilizing. Impurities in
glass can also interfere with sensitive molecu-
lar biology techniques. In addition, the waste-
water produced from the cleaning and
sanitizing process is an environmental trade-
off to reduced waste disposal.
Management of Unavoidable 
Medical Wastes
Generation of RMW from most biomedical
research facilities is unavoidable. This waste
must be collected, treated, and disposed of in
a manner that is safe, cost effective, and pro-
tective of the environment.
The primary objective of RMW treatment
is inactivation—reducing the concentration
of pathogens in the waste to levels not
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hazardous to public health and safety.
Secondary objectives may include a) encapsu-
lation or destruction of sharps; b) preventing
or retarding putrefaction and generation of
odors; c) physical alteration to remove aes-
thetically objectionable characteristics,
destroy conﬁdential patient or research infor-
mation, or render discarded materials unrec-
ognizable as medical waste; d ) volume
reduction; and e) stabilization of treated
wastes to minimize potential impacts on the
environment from ﬁnal disposal.
Currently, over 90% of medical wastes is
treated by incineration (26). However, recent
rulings (40) under the Clean Air Act (41) and
the Clean Air Act Amendments (42) are forc-
ing change. Under these new rules, existing
incinerators face costly retroﬁtting or possible
closure in favor of newer incinerators capable
of complying with the new standards. EPA
anticipates that many older, hospital-based
units will shut down within the next three
years and newer off-site, commercial units
will be used at full capacity. 
Reductions in the use of on-site incinerators
and costs associated with shipping and dis-
posal at commercial facilities are also encour-
aging rapid development and greater use of
alternate (nonincineration) treatment tech-
nologies for solid medical wastes. These
include systems using chemical disinfectants,
low-pressure steam sterilization (autoclaves),
high-pressure steam (steam reforming),
microwaves, radiation, plasma arc pyrolysis,
alkaline hydrolysis (tissues and animal car-
casses), and other specialized methods for
narrowly classified waste streams. Usually,
some combination of technology options
must be used, because most alternate tech-
nologies cannot be used to process all of the
various types of RMW generated by biomed-
ical research facilities. For example, autoclaves
are not suitable for treating waste that con-
tains chemotherapeutic drugs, and only a few
autoclave systems are approved for the treat-
ment and destruction of pathological wastes. 
Many manufacturers provide alternative
treatment systems, and disposal services using
some of the technologies are now commer-
cially available. Each of these technologies has
specific strengths and weaknesses that must
be carefully examined and matched with the
unique needs, waste streams, priorities, and
circumstances of each generator. Guidance on
evaluating and selecting treatment and dis-
posal methods for RMW may be found in
references listed on the EPA Medical Waste
Home Page (43) and reviews (44,45). 
Current Issues Affecting Management
of RMW
Uniform definitions and regulations for
management of RMW are needed. The vary-
ing deﬁnitions of RMW and requirements for
its management imposed by different Federal
agencies, states, and local governments can
cause confusion and add unnecessary costs to
managing RMW. This is particularly evident
when RMW must be shipped through multi-
ple jurisdictions to distant commercial facili-
ties for processing and disposal.
Some deﬁnitions of RMW are too broad,
and regulations may require excessive treat-
ment. Under some waste regulations, the mere
presence of materials from a biomedical labo-
ratory causes the waste to be considered bio-
hazardous and subject to regulation as medical
waste. Other regulations require treatment
steps not necessary to reduce risk. For exam-
ple, the Maryland statute uses the “reasonable
person perception rule” to define medical
waste. “Special medical waste,” a Maryland
term used for RMW, must be treated and ren-
dered nonrecognizable before it can be land-
ﬁlled (46). Other states permit recognizable,
autoclave-treated biohazardous waste to be
landfilled. Overregulation of medical waste
management increases costs and imposes
treatment requirements such as incineration,
which may more adversely effect the environ-
ment than burial of untreated waste.
The inclusion of criteria such as appear-
ance or waste origin in definitions of RMW
also complicates management of multihaz-
ardous wastes and may restrict access to
appropriate disposal facilities. Research proce-
dures frequently generate wastes with multi-
ple hazardous properties (see section
“Subcommittee on Multihazardous Waste”).
An appropriate method to manage multihaz-
ardous wastes with biohazardous properties is
to ﬁrst inactivate the pathogens that may be
present. The inactivated wastes can then be
shipped to facilities that have the appropriate
technologies for treatment and disposal of the
remaining hazardous constituents (hazardous
chemicals or radioactive materials). This may
not be feasible if the inactivated waste retains
its legal classification as RMW. Most haz-
ardous and radioactive waste disposal facilities
do not accept RMW because they do not
have the requisite permits or capability to
handle medical wastes. 
Evaluation criteria for alternate technolo-
gies should consider other contaminants typi-
cally present in RMW. Criteria for evaluation
of alternative medical waste treatment tech-
nologies are available (47). However, these
address only the effectiveness of the process in
inactivating pathogens. Medical wastes fre-
quently contain residues of antineoplastic
agents, drugs, and other hazardous, nonbio-
logical contaminants. Evaluation criteria
should be revised to include tests to deter-
mine the effectiveness of the technology in
treating these contaminants.
Conventional inactivation procedures may
be inadequate for inactivation of wastes
containing agents of transmissible degenerative
encephalopathy. Transmissible degenerative
encephalopathies (TDEs) such as scrapie and
Creutzfeldt-Jakob disease are the subject of
numerous research studies in progress.
Standard autoclaving, chemical disinfection,
and gas sterilization procedures effective for
inactivation of all previously known types of
pathogens may not be effective for inactivat-
ing the prior agents that cause TDE. These
agents are highly resistant to inactivation, and
accidental transmission has occurred with
inadequate decontamination procedures. A
recent study suggests that these agents may
even survive exposure to temperatures reached
during incineration of medical waste (48).
Standard inactivation methods should be
modiﬁed for treatment of wastes that may be
contaminated or potentially contaminated
with agents of TDE (49–51).
Management of medical wastes generated
outside facilities. Much of the medical waste
associated with biomedical research is gener-
ated by patients and healthcare providers in
homes and other areas outside facilities.
Research programs should provide guidance
to all participants on how medical wastes
should be managed. Guidance documents on
disposal of medical wastes from home health-
care are available (52–54).
Examples of Best Practices 
Source reduction program at a major hospital.
The New York Hospital in Queens, New
York, set a goal for its waste management
plan to conserve natural resources, minimize
the hospital’s impact on the community’s
resources, and refocus funding from waste
disposal to patient care. First, the hospital
created a “Green Team” to encompass all
levels of the organization, including the
board of trustees, the chairman, administra-
tion, nutrition services, nursing, building ser-
vices, quality management, materials
management, and human resources. The
team’s mission was to reeducate the entire
facility concerning waste reduction and con-
servation through phased projects. The first
phase focused on medical waste. The team
conducted a survey and found that items
such as paper towels, pizza boxes, intra-
venous (iv) tubing, and iv solution bags were
all being placed in red bags as RMW. With
this information, the team made changes in
the placement of waste containers such that
sorting of medical waste became easier. The
team then provided inservice training to edu-
cate staff about proper disposal. After initial
implementation, the team established a
schedule for periodic unannounced waste
surveys. On the basis of the surveys, the staff
was reeducated until they reached full com-
pliance. The effort reduced the volume of
RMW disposal by 71%.
 108S6.  12/11/00 2:31 PM  Page 958    (Black plate)MINIMIZATION AND MANAGEMENT OF WASTES FROM BIOMEDICAL RESEARCH
Clearinghouse for source reduction
information. Numerous additional examples
of best practices and case studies relating to
reduction of medical wastes and obtained
online from the EPA Waste Reduction
Resource Center (55), using the center’s P2
Info House information retrieval function
and entering the search term “medical waste.”
Development of alternate technologies by
biomedical research facilities. Some biomed-
ical facilities have been active in research and
development of alternate technologies for
treatment and disposal of RMW. An example
is the Biosafety Division of the Department
of Health, Safety and Environment, at Johns
Hopkins in Baltimore, Maryland, which has
been investigating for 8 years various alternate
technologies to replace medical waste inciner-
ation. Examples of technologies investigated
include grinding/microwave, grinding/
microwave/grinding, chemical/grinding,
autoclave/grinding, grinding/superheating,
and autoclave/liquid/grinding. The outcome
of this research was the successful develop-
ment of superheated water and steam liquid
grinding system that inactivates RMW and
produces a product that is not recognizable as
medical waste and is acceptable for direct dis-
posal as nonbiohazardous municipal waste.
The overall operating cost for the equipment,
including labor, was nearly half the contract
price to ship the waste to a regional medical
waste incinerator (56).
Subcommittee on Chemical
Wastes
This section presents information relating to
management of chemical wastes (hazardous
wastes). Pharmaceuticals are addressed in the
section “Subcommittee on Pharmaceutical
Wastes”; chemical wastes containing radio-
active materials or biohazardous agents are
addressed in the section “Subcommittee on
Multihazardous Wastes.”
Classiﬁcation and Characterization 
of Chemical Wastes
Classification. Chemical wastes may be
divided into the following groups: a) haz-
ardous wastes regulated under RCRA (e.g.,
flammable solvents, acids, bases, toxic met-
als); b) special wastes regulated under other
laws (e.g., polychlorinated biphenyls, used
oil); c) nonregulated hazardous wastes (e.g.,
ethidium bromide, aflatoxin); d) chemically
contaminated laboratory materials (e.g.,
papers, gloves, glassware); and e) nonhaz-
ardous chemical wastes (e.g., sugars, buffers).
Sources. As a broad generalization,
biomedical research facilities produce smaller
amounts and a larger variety of chemical
wastes and mixtures than industry, which
produces large amounts of a small number of
chemical wastes. Because individual research
laboratories tend to conduct unique research,
large institutions can use a large number of
different chemicals. For example, NIH has
over 625,000 chemical compounds in use or
in repositories. Most of these chemicals are in
quantities of < 100 g. The regulated haz-
ardous and special wastes produced by bio-
medical laboratories are primarily mixtures of
organic solvents, with lesser amounts of other
materials such as used oil, contaminated lab-
ware, and miscellaneous chemicals.
Activities that result in chemical wastes
primarily include a) disposal of excess, out-
dated, and off-specification chemicals; b)
molecular biology procedures (e.g., extrac-
tion, purification and sequencing of nucleic
acids, proteins); c) analytical procedures (e.g.,
assays, gel electrophoresis); d) histological
procedures (e.g., fixatives, stains); e) other
experimental uses of chemicals; f ) cleaning
and disinfection; g) care and maintenance of
laboratory animals; h) ﬁlm processing; i) facil-
ity operations (e.g., paint, ﬂoor cleaners, ﬂoor
strippers, batteries, fluorescent light tubes,
and ballasts); and j) disposal of contaminated
labware and spill clean-up residues. More
detailed information of the hazardous sub-
stances produced by speciﬁc biomedical pro-
cedures is available (57–59).
Quantities generated. In analyzing poten-
tial economic impacts on various economic
sectors prior to the adoption of the first
RCRA regulations in 1980, EPA estimated
that academic institutions—a group larger
than biomedical laboratories—generated less
than 1% of the nation’s hazardous waste (60).
There are no indications that this proportion
has changed over the past 20 years.
Assessment of the Potential for
Environmental Impacts from Chemicals
in Wastes from Biomedical Research
Approach. The committee sought to develop
a preliminary assessment of the risks posed to
the environment from chemicals used in bio-
medical research facilities, and based on this
assessment, determine which of the myriad
chemicals in use should receive priority in
planning minimization efforts. The assess-
ment was performed by collecting data on
chemicals present in hazardous wastes from
research facilities and comparing the data
with lists of chemicals that pose the greatest
threat to the environment. The approach
used in this assessment followed that estab-
lished in the EPA Waste Minimization
National Plan (61), and probably represents
the ﬁrst attempt to apply the methodologies
recommended in the plan to BRW.
Persistent, bioaccumulative and toxic
chemicals list. For this assessment, chemicals
identified by EPA as persistent, bioaccumu-
lative, and toxic (PBT) were assumed to
pose the greatest potential threat to the
environment. PBT chemicals do not break
down or decrease in potency when released
to the environment, even if released in very
small, legally permitted quantities. Over
time, these chemicals are likely to accumu-
late in soils or other environmental media.
The chemicals can also be absorbed or
ingested by plants and animals, accumulate
in animal tissues to be passed through the
food chain, and potentially cause long-term
human health effects such as cancer or eco-
logical problems. Several initiatives have
been developed that place a focus on PBT
chemicals identified by the Waste
Minimization National Plan. The draft
RCRA PBT List published in 1998 (62) was
used in this assessment and consisted of 53
chemicals.
Collection of waste generation data.
Waste generation data for this assessment
were obtained from three facilities: the NIH
main campus at Bethesda, Maryland (63), the
National Institute of Environmental Health
Sciences (NIEHS) campus at Research
Triangle Park, North Carolina (64), and the
R.W. Johnson Pharmaceutical Research
Institute (RWJPRI) (65) at Spring House,
Pennsylvania. These facilities were selected
because all of their wastes are from biomed-
ical research activities, and the facilities were
representative of different types of research
programs. Wastes generated in 1998 from
approximately 4,000 laboratories, animal care
facilities, and the NIH Clinical Center (CC),
a major research hospital, are included in the
NIH data. NIH waste accounting system
allowed the estimation of net weights of spe-
cific chemicals in wastes by concentration-
based calculations for every waste container
received for disposal. Data for NIEHS were
compiled from chemical name listings and
gross weights in hazardous waste generation
records from 1998; data from concentration-
based calculations were not available. For
NIH and NIEHS, a descending rank order
listing of all hazardous chemicals generated in
1998 was produced. The top 100 chemicals
(by total weight generated) for each facility
were used for comparison with the list of
PBTs. Quantitative data were not available
from the RWJPRI; however, a representative
of the facility was asked to compare the con-
stituents typically present in their wastes with
the NIEHS and NIH rank order listings and
the PBT list and to report any significant
differences in chemical use and disposal.
Results. The assessment was performed
and reported by Borenstein and Radzinski
(66). Results are summarized in Table 2. The
characterization of PBTs in the wastes from
the three facilities was similar and suggests
that the chemicals present in wastes from
research facilities present a low potential for
adverse impacts on the environment: 
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• The top 100 chemical lists from NIH and
NIEHS included 156 different chemicals.
Of these, only 15 (~10%) are currently on
the draft RCRA PBT list. Of the 156
compounds, 79 chemicals (51%) were
not considered PBTs. The remaining
chemicals were either not speciﬁcally eval-
uated or their PBT status could not be
determined from the information
presented. For instance, the elemental
forms of some heavy metals are classiﬁed
as PBTs. However, except for mercury
and lead, their compounds are not. On
the other hand, cyanides, and insoluble
oxide/hydroxide forms are problematic
and currently are classiﬁed as PBTs.
• The PBTs present in the wastes in the
highest amounts were organic com-
pounds, primarily chloroform and phe-
nol. With the exception of these two
compounds, the PBTs present in the
wastes were minor constituents of the
wastes from these facilities.
• With the exception of chromium, heavy
metal PBTs are minor constituents of the
hazardous waste streams from laboratories
at all three facilities. Chromium com-
pounds ﬁnd limited use in certain staining
procedures and in cleaning glassware.
Signiﬁcant quantities of lead, nickel, and
cadmium, and small amounts of mercury
were generated by the NIH and NIEHS
facilities. These were components of dis-
carded articles (batteries, shielding, and
laboratory apparatus), which were shipped
to recycling facilities for reclamation.
Recycled metals were not included in
rank order calculations.
• Some differences in the chemicals found
in wastes and their rank order were noted
among the three facilities, which probably
reﬂect differences in their research focus.
Wastes from NIH are primarily generated
from molecular biology procedures (DNA
and protein extraction, sequencing, and
synthesis). NIEHS, although organiza-
tionally part of NIH, conducts research
on environmental health and toxicology.
The RWJPRI is involved in drug investi-
gation and development activities. The
notable differences between PBTs in
wastes from the RWJPRI and the NIH
facilities were the presence of nitroben-
zene, which was not reported in wastes
from NIH and NIEHS, and signiﬁcantly
lower levels of chloroform and phenol in
the wastes from the RWJPRI.
The subcommittee concludes that poten-
tial chemical hazards from biomedical
research wastes are probably of most signifi-
cance to laboratory workers and secondarily
to persons who might be accidentally
exposed to small volumes of acutely haz-
ardous wastes. Because relatively small
amounts of hazardous chemicals are used in
biomedical research, and most of these are
not PBTs, chemicals in BRW present an
insignificant hazard to the general environ-
ment. There are currently adequate numbers
of commercial facilities available to handle
virtually all hazardous wastes generated from
biomedical research. 
Table 2. Prevalence of persistent, bioaccumulative, and toxic chemicalsa in hazardous wastes from three biomedical
research facilities.
Presence of chemical in facility wastes
Chemical Abstracts Pharmaceutical
Registry No. Chemical name NIHb NIEHSc research laboratoryd
101553 4-Bromophenyl phenyl ether
83329 Acenaphthene
208968 Acenaphthylene
120127 Anthracene
7440360 Antimonye,f
7440382 Arsenice • ••• Yes
191242 Benzo(g,h,i)perylene
7440417 Beryllium
117817 Bis(2-ethyhexyl)phthalate
85687 Butyl benzyl phthalate
7440439 Cadmiume,f • Yes
67663 Chloroform •••• •••• Yes
7440473 Chromiume,f •• ••• Yes
7440508 Coppere,f • Yes
57125 Cyanide • •• Yes
84742 Dibutyl phthalate • Yes
95501 1,2-Dichlorobenzene
541731 1,3-Dichlorobenzene
106467 1,4-Dichlorobenzene
75343 1,1-Dichloroethane • Yes
959988 Endosulfan, alpha
33213659 Endosulfan, beta
206440 Fluoranthene
86737 Fluorene
76448 Heptachlor
1024573 Heptachlor epoxide
118741 Hexachlorobenzene
87683 Hexachlorobutadiene
58899 Hexachlorocyclohexane, gamma
7439921 Leade,f • • Yes
7439976 Mercurye,f • • Yes
72435 Methoxychlor
91576 2-Methylnaphthalene
91203 Naphthalene ••
7440020 Nickele,f • Yes
98953 Nitrobenzene Yes
29082744 Octachlorostyrene
608935 Pentachlorobenzene
82688 Pentachloronitrobenzene
87865 Pentachlorophenol •
85018 Phenanthrene
108952 Phenol •••• •••• Yes
732263 Phenol, 2,4,6-tris(1,1-dimethylethyl)-
None Polychlorinated dibenzofurans 
None Polychlorinated dibenzo-p-dioxins 
None Polycyclic aromatic compounds
129000 Pyrene
7782492 Seleniume Yes
95943 1,2,4,5-Tetrachlorobenzene
120821 1,2,4-Trichlorobenzene
71556 1,1,1-Trichloroethane
95954 2,4,5-Trichlorophenol
7440666 Zince,f •
Rank by total net weight in wastes from NIH and NIEHS facilities in 1998:
••••  Top 20 chemicals
•••  Top 21–60 chemicals
•• Top 61–100 chemicals
• Not present in top 100 but greater than 1 kg (NIH) or 0.1 kg (NIEHS) disposed of per year
aChemicals on the EPA Draft RCRA Waste Minimization PBT chemical list (62). bBased on combined data for all NIH facilities in
Maryland and the District of Columbia excluding the Frederick Cancer Research and Development Facility at Frederick, Maryland (63).
cBased on combined data for all NIEHS laboratories at Research Triangle Park, North Carolina, facility (64). dBased on nonquantitative
data from R.W. Johnson Pharmaceutical Research Institute Laboratory (65). eData include compounds of the listed element. fDoes not
include metal content of batteries, shielding, and other articles that are recycled and not disposed of as hazardous waste.
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Planning for Chemical Waste
Minimization 
An effective hazardous waste minimization
program requires careful planning and imple-
mentation. A great deal of information has
been published on preparing a waste mini-
mization program, but most such programs
need to be customized to each facility.
Programs should include waste characteriza-
tion and accounting systems so trends can be
evaluated and opportunities for waste mini-
mization can be identified in planning, set-
ting reduction goals, and tracking
performance. The following steps are helpful
in identifying good candidates for minimiza-
tion: a) use materials acquisition and waste
generation data to identify the chemicals used
and disposed of in the highest amounts; b)
match these against the list of PBT chemicals
as well as other risk-based lists of chemicals; c)
determine the feasibility of implementing
source reduction activities; d) calculate the
cost effectiveness; e) select and prioritize
wastes for minimization efforts based on the
assessment information gained from the
previous steps.
At NIH, for example, chloroform, phe-
nol, and lead have been identified by waste
accounting systems as the three highest vol-
ume PBT chemical wastes. All three are
amenable to source reduction techniques
without placing burdens on research. For
most radionuclides used in laboratories, other
less-toxic alternatives to lead shielding are
available, and use of nonradioactive methods
eliminates the need for shielding entirely.
Much of the chloroform and phenol is used
for extraction and purification of nucleic
acids. There are now substitute methods suit-
able for many applications that don’t use
these chemicals. Regarding the cost effective-
ness of source reduction, phenol and chloro-
form are most often disposed in lab packs,
which have a high cost/volume ratio. Lead is
relatively inexpensive to recycle. However,
when it gets contaminated with radioactive
material or contaminates radioactive waste,
the resulting mixed waste can be extremely
expensive problems for facilities to deal with.
Many different risk-related criteria can be
used for establishing priorities for minimizing
wastes. The EPA PBT list is an obvious start-
ing point. Data on other risk factors such as
acute toxicity, mutagenicity, carcinogenicity,
and endocrine disruption potential should be
used as well. Use of such data is particularly
important for chemicals that are primarily
used in research rather than industrial appli-
cations, because most of these chemicals have
not been evaluated for placement on priority
lists. Several EPA publications (17,67,68)
provide general guidance on prioritizing
waste streams for minimization. Facilities
should set waste minimization priorities based
on criteria most important to their specific
operational activities.
Source Reduction Strategies 
Several steps should be taken in biomedical
research laboratories to minimize chemical
waste generation.
Use standard operating procedures. The
preparation of standard operating proce-
dures (SOPs) for common and repeated lab-
oratory procedures offers the potential to
significantly reduce chemical waste genera-
tion. Usually SOPs are driven by the desire
to achieve reproducible, reliable, and accu-
rate experimental results. When writing such
procedures, consideration should also be
given to the chemicals and quantities used,
and the disposition of these materials with
the goal of minimizing wastes. SOPs should
be reviewed periodically to determine if the
amount and/or toxicity of wastes could be
further reduced.
Establish and maintain a chemical
inventory system. Many facilities have suc-
cessfully utilized computerized chemical
management systems in combination with a
pharmacy-type distribution facility to assist
with inventory control and tracking of chem-
icals. Such systems signiﬁcantly reduce waste
generation (69,70). Minimally, the facility
should maintain a record of users of speciﬁc
chemicals. Such lists can offer the opportu-
nity for decreasing the amounts of chemicals
procured by reducing duplication of orders
and sharing common chemicals among
investigators.
Redistribute excess chemicals for beneﬁcial
use. All institutions should have a program to
redistribute excess chemicals that are still in
good condition. These programs take excess
chemicals of suitable quality that laboratories
inevitably accumulate and find other
researchers who can make use of them. Such
programs save money by avoiding both pur-
chase and disposal costs. Essential operating
features of redistribution programs include a)
developing criteria for determining what
chemicals are suitable for redistribution and
quality assurance procedures; b) providing a
safe and secure repository area for chemicals
pending redistribution; c) establishing policies
on how long chemicals remain in storage; d)
publicizing (marketing) the availability of
such chemicals; and e) appointing a qualiﬁed
person to be in charge of the chemical reposi-
tory. (Shared responsibility does not work.)
Ensure complete identiﬁcation of chemicals.
All chemical containers should be labeled
indicating the chemical names(s) of their con-
tents. Codes, acronyms, and other obscure
identiﬁers should be avoided. This is particu-
larly important for samples of chemical inter-
mediates and final products held for future
reference. These items often lose their
identity once their original owner leaves the
work site. Such unknown samples become
very difﬁcult to manage and cannot be trans-
ported or disposed of without accurate and
complete identiﬁcation. 
Reduce the size of experiments. This can
be accomplished by minimizing the volume
of reactants, using microscale techniques,
carefully selecting the appropriate experimen-
tal design (factorial, partial factorial, etc.) and
the number of replicates required.
Manage chemical procurement. Avoid
purchasing excess quantities of chemicals.
Encourage investigators to order only what is
needed for the next 3–6 months or on com-
pletion of a protocol.
Segregate hazardous wastes. This step
increases recycling and management options.
Keep hazardous wastes separate from biohaz-
ardous, radioactive, and nonhazardous wastes.
Maintain good housekeeping. This will
help reduce spills and contamination. Areas
where hazardous chemicals are stored and
used should be conﬁned to minimize size of
the areas subject to contamination and spills.
Avoid overuse of absorbents, liners, etc. that
may require management as chemical waste.
Management of Wastes
Some generation of chemical wastes from
biomedical research is unavoidable. Once
source reduction strategies have been
exhausted, management options must be
selected to minimize the volume and toxicity
of wastes and the potential environmental
impacts of waste treatment and disposal. The
strategies below are presented in their general
order of desirability from the standpoint of
environmental protection.
Recycling. Recycling processes usually
require wastes to be reprocessed or reclaimed
before their constituents can be used for ben-
eﬁcial purposes. Examples of recycling strate-
gies for laboratories include a) separate
collection of used solvents with only trace lev-
els of contamination for use in washing pur-
poses; b) distillation recovery of solvents for
reuse (refer to examples of best practices); and
c) segregation of wastes that have reclamation
value, such as used oil, mercury, scrap lead
and precious metal compounds, and solvents
suitable for use in fuel recovery facilities.
Treatment. In-laboratory treatment
(71,72) can be a valuable tool to minimize
volumes of waste and reduce hazards from
the handling, transportation, and disposal
of hazardous wastes. Due to RCRA con-
straints, treatment of laboratory wastes
should be limited to small amounts of
chemicals used in experimental procedures
and acid/base neutralizations. All treatment
procedures must be carefully evaluated to
ensure worker safety, effectiveness, and
regulatory compliance.
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Consolidation. Small containers of chemical
wastes are usually packaged for shipment and
disposal in lab packs (drums or other contain-
ers ﬁlled with absorbent material). Some facil-
ities reduce the numbers of lab packs shipped
off-site by consolidating the contents of small
containers of compatible wastes into larger
bulk containers such as 55-gal drums. This
can substantially reduce shipping volumes
and disposal costs. Consolidation activities
usually are not considered treatment and do
not require EPA permits. However, they
should never be undertaken without adequate
facilities and equipment, a thorough safety
review, and preparations for spills.
Disposal. From the standpoint of environ-
mental protection, disposal is the least desir-
able option in the heirarchy of methods used
for managing chemical wastes. Disposal
methods for chemicals regulated as hazardous
waste are dictated by the EPA and states. For
nonregulatted chemicals, the generator may
determine the disposal method. In most
cases, nonregulated chemicals that have
unknown or potentially hazardous properties
should be disposed of as hazardous waste,
using incineration or other methods that
assure their destruction and prevent toxic
emissions. Nondestructive methods such as
releasing wastes to the sanitary sewer or dis-
posal or in landfills are only appropriate for
sugars, buffers, and other low-hazard, nonreg-
ulated chemicals. 
Regulatory Issues
Overview of existing regulations. Regulation
of hazardous wastes under RCRA has been in
place for almost 20 years. These regulations
are very speciﬁc in deﬁning what is regulated
as a hazardous waste and how these wastes
must be disposed. Hazardous wastes are
tracked from the time they are generated
through their ﬁnal disposal at permitted haz-
ardous waste disposal sites. There are limits
on the amounts kept in storage and the
length of time waste can be stored. Waste
containers must be compatible with the
wastes they contain, properly labeled, and
kept closed except when in use. There are
requirements for training and emergency
response. Generators of hazardous waste are
required to plan for minimization of wastes
and must certify on each manifested ship-
ment of hazardous wastes off-site that they
have reduced the volume and toxicity of the
waste to the maximum extent practical.
In addition to the regulations adopted
pursuant to RCRA, regulatory schemes pro-
mulgated after several other statutes affect the
management of hazardous wastes in biomed-
ical laboratories. These include the following:
Clean Water Act of 1977—CWA (33); Clean
Air Act—CAA (41); Comprehensive
Environmental Response, Compensation and
Liability Act—CERCLA (73); Hazardous
Materials Transportation Act—HMTA (74);
Superfund Amendments and Reauthorization
Act of 1986—SARA (75); and Toxic
Substances and Control Act—TSCA (76).
Regulatory impediments to effective man-
agement. Biomedical research generates rela-
tively small quantities of a large variety of
wastes and the composition of these wastes
varies dramatically over time. Because RCRA
prescribes detailed characterization and track-
ing requirements for all regulated wastes
regardless of volume, disposal of wastes from
biomedical research laboratories entails a large
amount of paperwork for a relatively small
amount of waste. Larger biomedical research
institutions may encounter regulatory diffi-
culties in administrative areas that have little
to do with sound hazardous waste manage-
ment. For example, institutions that are not
contiguous must obtain multiple generator
identification numbers. Once this happens,
transfer of wastes to a central management
facility creates additional regulatory burdens
due to manifesting requirements. In some
cases, it may be determined that the central-
ization of waste management activities is not
legal without a Part B permit, which is difﬁ-
cult and costly to obtain. Some regulators
have imposed hazardous waste training
requirements on researchers that appear to be
excessive relative to their involvement in haz-
ardous waste management activities.
Institutions have questioned the numbers of
researchers that must be trained and the
extent of training required. Unnecessary,
redundant or excessive training efforts con-
sume resources that could be used more pro-
ductively elsewhere in the institution.
Examples of Best Practices
Chemical redistribution program. Laboratory
chemical redistribution programs (chemical
exchanges) have been in place at NIH and
many university and college campuses for
some time. Improvements in information
technology and computer networks have fos-
tered the development of these exchange pro-
grams and greatly improved the efﬁciency of
their operations. Automated systems now
allow the posting of instantaneously updated
inventories of surplus chemicals, searching for
needed chemicals, and in some cases the plac-
ing of surplus pick-up and delivery orders. An
example of such a system is found on the
NIEHS campus. When researchers at the site
have excess reagents, they send E-mail
messages that broadcast to other researchers. 
To increase the potential for reuse of
surplus chemicals, some institutions have
expanded the reach of chemical redistribution
programs beyond their own facilities. An
example is a program initiated several years
ago by Bowling Green State University
(Bowling Green, Ohio). They expanded their
existing orphan chemical recycling program
to include nonuniversity academic institu-
tions such as technical colleges, high schools,
junior high schools, some nonacademic facili-
ties, and a local hazardous waste management
company. The expanded program was highly
successful, resulting in the transfer of 2,000
pounds of solid chemicals and 475 gallons of
liquids chemicals to needy institutions and
facilities. The dual cost savings associated
with these transfers (for avoidance of pur-
chase and disposal costs) were estimated to be
between $150,000 and $180,000 after
approximately the ﬁrst year of operation (77).
Recovery of waste solvents by distillation.
Biomedical research facilities can generate sig-
nificant amounts of waste solvents. On-site
recovery for reuse of high volume solvents by
batch distillation can be a cost-effective tech-
nique. An example of such a recovery opera-
tion was provided by NIEHS (64). A review
of the volumes of waste xylene and ethanol
solvents generated by a centralized histology
services operation led to successful develop-
ment of an on-site waste solvent distillation
and recovery operation as part of the overall
laboratory waste minimization program at the
institute. Critical to the success of the pro-
gram was involving the end users in the initial
steps taken to deﬁne acceptance criteria for the
recycled solvent and ensure quality control.
The committee received reports of other
facilities successfully recovering waste xylene
and ethanol from histology operations (78).
However, no reports of successful recovery of
solvents from other laboratory uses were
found. Barriers to recovery of these other sol-
vent waste streams include the high capital
cost of equipment, technical difficulties in
separating pure solvents out of mixtures, reg-
ulatory concerns (some states may require
permits), and acceptance of recovered sol-
vents by the users. Therefore, distillation
must be evaluated by each institution and
many will find that other pollution preven-
tion activities are more desirable.
Water conservation. An often overlooked
resource in the laboratory is the water supply.
Although the use of high- or ultra-purity
water (e.g., deionized, distilled, 18 meg-ohm)
is usually well managed through experimental
protocols, the use (or misuse) of tap water is
often ignored. Because high volumes of tap
water are used in rinsing, cooling, and wash-
ing operations, costs associated with waste-
water treatment and disposal can be
significant. Investigators should consider
water conservation opportunities in their
ordinary tap water usage. For instance,
instead of using water-cooled condensers on
permanent experimental setups, a recirculat-
ing coolant system is more water resource
efficient. Tap water should not be left
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running in the laboratory sink. Similarly,
vacuum service should be obtained from the
laboratory service taps, or when not available,
by vacuum pumps, instead of using water
aspirators operated at the sink.
Mercury reduction programs. The com-
mittee found many examples of best practices
for minimization and management of speciﬁc
chemical wastes generated by biomedical
research facilities. This section highlights
examples of best practices to reduce the use of
mercury and mercury-containing products.
While mercury represents a small portion of
the PBTs generated by research facilities, the
potential for spills and exposures, high decon-
tamination and disposal costs for items conta-
minated with mercury, and extremely low
allowed discharge limits for mercury in waste-
water have caused many facilities to assign
high priority to mercury reduction efforts.
These examples illustrate how focused pollu-
tion prevention initiatives can greatly reduce
or eliminate problematic chemical waste
streams in biomedical facilities.
Mercury reduction program at a research
hospital. The NIH Warren G. Magnuson CC
is a tertiary-care Federal hospital where NIH
clinical investigators study human diseases. In
1996, CC employees addressed emerging clin-
ical and safety concerns about the use of med-
ical devices containing mercury. Data from
the chemical spill responders and hospital haz-
ard surveillance teams supported the safety
committee’s recommendation that the CC
reduce its use of mercury-containing devices.
At the same time, the Standardization
(Equipment) Committee needed to purchase
automated blood pressure monitoring equip-
ment to meet changes in the standard of care
for conscious sedation, a higher risk medical
procedure recommended by both accredita-
tion and professional organizations. After dis-
cussions with the stakeholders, the CC
purchased mercury-free thermometers and
sphygmomanometers for all new and existing
applications. These included aneroid or
mechanical blood pressure monitors and
infrared and digital thermometers for routine
use, and more sophisticated systems capable of
measuring patient vital signs (blood pressure,
temperature, and pulse rate) on a continuous
basis for monitoring patients during conscious
sedation. Mercury-containing devices were
considered by many clinicians to be the gold
standard, and their replacement with nonmer-
cury devices was not without controversy at
the CC or other institutions (79–81). This
was anticipated by the proponents of the CC
mercury reduction project, and steps were
taken to involve the medical community early
on and to address their concerns. On the basis
of this experience, these steps should be
undertaken in implementing similar reduction
projects in other facilities:
a) Inform and involve all of the stake-
holders including administration, clinical
staff, biomedical engineering, and environ-
mental safety personnel throughout the deci-
sion-making and implementation process. 
b) Conduct a comprehensive search to
identify all mercury-containing devices within
the facility that may have alternatives. The
CC identified safer alternatives to replace
mercury esophageal dilators, canter tubes,
and glass barometers and thermometers used
for calibrating laboratory equipment (82).
c) Avoid requiring across-the-board elimi-
nation of mercury devices when alternatives
may not be suitable. For example, infrared
thermometers may not meet the clinicians’
needs for certain patients (83–87).
d) Monitor trends among medical suppliers
who are eliminating their use of mercury in
their equipment. During the project, the CC
learned that several manufacturers planned to
phase out the production of mercury-contain-
ing equipment, ensuring that mercury-free
replacements would be an inevitable event. 
e) Divide the project into phases and set
priorities for the removal of higher risk items
(e.g., those frequently associated with haz-
ardous spills). This portion of the CC mer-
cury reduction project resulted in the removal
of more than 1,500 mercury-containing med-
ical devices and was completed without a spill
incident or interruption in patient care. 
Comprehensive program for tracking and
elimination of mercury in facility effluent.
Facing a technically difficult requirement to
achieve a near-zero limit on mercury in waste-
water, several hospitals and universities in the
Boston area agreed to work with the
Massachusetts Water Resources Authority
(MWRA) and the Medical Academic and
Scientific Community Organization, Inc.
(MASCO), a consortium of local institutions,
in developing a comprehensive control pro-
gram. This included investigation of occult
sources of mercury in products used by their
institutions, development of source reduction
measures, and evaluation of treatment tech-
nologies for removal of mercury from plumb-
ing systems and wastewater. Source reduction
methods developed by the program and
actions to remove mercury-containing biomass
from piping systems were the most successful
approaches found and resulted in reductions of
the average concentration of mercury in waste-
water discharges from participating institutions
by 80%. A description of the program, lists of
recommendations, and resource materials
are available from the MWRA/MASCO
cooperative work group (88).
Subcommittee on
Pharmaceutical Wastes
Biomedical research facilities directly dispose
of small quantities of unused drugs and
wastes contaminated with drugs in the course
of their operations. The total amount of
drugs disposed of by biomedical facilities is
negligible when compared with that disposed
of by society. However, drugs are primary
products of research, and the impacts of their
use and disposal on human health and the
environment should be addressed by the bio-
medical research community.
The pace of biomedical research and
development is increasing rapidly, and this
has the potential to signiﬁcantly increase the
generation of waste drugs, manufacturing
intermediates, and wastes contaminated by
these substances. A 1999 survey reported
354 medicines currently in development for
cancer alone (89). According to the
Pharmaceutical Research Manufacturers
Association, pharmaceutical companies
invested $24.0 billion in research and devel-
opment in 1999, a 14.1% increase over
1998 (90). 
Sources of Waste Drugs 
and Related Wastes
The primary sources of drug wastes are phar-
maceutical research, development, and manu-
facturing, and the use of drugs by patients.
Only a very small percentage of the drugs dis-
posed of by facilities and patients is unused.
Pharmaceutical research and development.
The quantities and compositions of drug-
related wastes generated during biomedical
research activities depend on many factors,
including the phase of research and the type
of facility.
During the drug development phase,
drug-related wastes may include compounds
under investigation for potential use; chemi-
cals used to analyze, extract, or synthesize
investigational drugs; agents used in molecu-
lar studies; drugs used for testing in labora-
tory animals; and veterinary drugs used for
care of laboratory animals.
Only about one out of every thousand
compounds that undergo testing in the devel-
opment phase reaches the clinical trial phase
(91). However, wastes from the clinical trials
may be more likely to be released into the
environment, because wastes from this phase
are usually not managed in larger, centralized
facilities that tend to have well-developed
waste minimization and disposal procedures. 
During the clinical trial phase the drug
wastes may include investigational drugs,
standard-of-care drugs used to compare ther-
apeutic efﬁcacy of new drugs, and drugs used
for the diagnosis and treatment of patients.
Drug wastes may be in several forms:
unused, expired, and residual drugs as solids
and liquids; wastewater from cleaning areas
contaminated during the mixing and admin-
istration of pharmaceuticals; and solid wastes
contaminated with drugs. 
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Once pharmaceuticals have reached the
later stages of clinical trials and after they are
approved for clinical use, they are typically
administered and disposed of in small health-
care facilities and households, settings where
there are virtually no requirements governing
disposal, and little or no guidance on appro-
priate disposal methods is provided to
patients.
Patient excreta. Patient excreta are the
primary source of drug contaminants in the
environment. Data in the Physicians’ Desk
Reference (92) indicate that for many widely
prescribed drugs, from 50 to 80% of a
patient’s intake of a drug is excreted as
unmetabolized drug or active metabolites.
Regulation of Drug Waste Disposal
Regulations governing disposal of unused
drugs vary among countries. Some countries
such as Great Britain regulate disposal of all
unused prescription medicines (93). In the
United States, few regulations govern disposal
of unused drugs, except for those that are
specifically regulated as hazardous wastes or
controlled substances. Disposal practices for
drug wastes vary widely between facilities and
are determined by the type of drugs present
in the waste, the form of the waste, size of the
facility and institutional considerations.
Drugs regulated as hazardous wastes. Of
the hundreds of thousands of compounds
and formulations that are in use or being
investigated for potential use as drugs, only
18 are subject to regulation as hazardous
waste by EPA (Table 3). The scope of regula-
tions is very limited even for the listed drugs.
The regulations generally do not apply to
used drugs, drugs that are not considered
commercial products, drugs in formulations
that contain multiple active ingredients,
unused drugs disposed of by households, and
domestic sewage.
The requirements for management of
drugs regulated as hazardous wastes also vary
with the type and size of the facility. Waste
generators are grouped into three categories
based on the total amounts of hazardous
wastes that they generate: large quantity gen-
erators, small generators, and conditionally
exempt small-quantity generators (CESQGs)
(96,97). Major research facilities are likely to
be large generators and are subject to the most
stringent regulations. Facilities that are likely
to be CESQGs and subject to minimal regula-
tion typically include small hospitals, clinics,
nursing homes, assisted living facilities, and
retirement communities. (It is of concern that
these CESQGS often have the highest con-
centrations of people using multiple medica-
tions.) In most states, some generators such as
households are exempt from all regulations. 
Drugs and intermediates regulated as
controlled substances. Controlled substances
include narcotics and other drugs that may be
abused. They are subject to special licensing,
ordering, storage, handling, use, and disposal
requirements under the Controlled
Substances Act (98), which is enforced by the
U.S. Drug Enforcement Administration
(DEA) (99–101). Disposal procedures for
controlled substances generated by pharma-
cies, laboratories, and medical facilities are
regulated by the DEA and state agencies.
These procedures are primarily intended to
prevent diversion and abuse, not to protect
the environment. Once a drug is prescribed,
patients may dispose of any personal con-
trolled substance in any manner they choose. 
Chemical intermediates. Chemical inter-
mediates used to synthesize drugs may be reg-
ulated as hazardous waste if they are
speciﬁcally listed as hazardous wastes by EPA
or have certain hazardous characteristics such
as ignitability, corrosivity, or leachate toxicity.
Drugs and intermediates subject to both
EPA and DEA regulations. On the DEA list
of scheduled substances, only one com-
pound, phenylacetone (Schedule II), may
also be regulated by EPA as an unlisted haz-
ardous waste. The Chemical Diversion and
Trafficking Act of 1988 (102) resulted in
regulation of additional nondrug chemicals
that were being diverted from legitimate uses
to illegal production of controlled sub-
stances. Control of specific chemicals was
further expanded in 1993 and 1994 by the
Domestic Chemical Diversion Control Act
(103). This required tracking of transfers and
registration of manufacturers, distributors,
importers, or exporters of listed chemicals.
Some of these are also regulated as hazardous
wastes by EPA if they exhibit defined
hazardous characteristics such as ignitability.
Some states regulate additional controlled
substances as listed hazardous wastes. 
Drugs and chemicals that are regulated as
both scheduled substances and hazardous
wastes may be highly problematic to dispose
of, as both EPA and DEA regulations must
be followed. Some of the regulatory problems
in managing waste controlled substances have
been acknowledged by the DEA (104). 
Solid wastes contaminated with cytotoxic
drugs. Solid wastes contaminated with cyto-
toxic drugs are generated during formulation
and administration of the drugs to patients.
NIH and many other biomedical research
facilities handle these contaminated solid
wastes as regulated medical waste and dispose
of them by incineration (105).
Drugs not subject to EPA or DEA regula-
tion. The disposal of most drugs is not regu-
lated and disposal is left to the discretion of
the owner. Disposal of unregulated drugs in
the sanitary sewerage system is a common
practice, especially in smaller facilities and
households. Pharmacy operations at research
facilities may have procedures in place to
return unused drugs to pharmaceutical man-
ufacturers or arrange for secure disposal at
commercial medical waste facilities.
Incineration as medical waste is believed to
provide adequate treatment. However, the
current trend toward alternate (nonincinera-
tion) technologies for disposal of medical
wastes is of concern. The efficacy of these
alternate methods in assuring destruction of
drugs has not been investigated. 
Disposal via wastewater systems. Unused
drugs and drug-contaminated liquids such as
wastewater from mixing drugs and cleaning
areas contaminated with drugs are usually dis-
charged to the sanitary sewer. In most bio-
medical facilities, wastewater from the
preparation of cytotoxic agents is an excep-
tion, because it is usually managed and dis-
posed of as medical waste or hazardous waste. 
Disposal with general solid wastes.
Unused drugs and materials contaminated
with drug residues may also be discarded
with other solid wastes. Municipalities dis-
pose of these wastes in sanitary landﬁlls or by
incineration.
Disposal of unused drugs by patients.
Patients accumulate excess, outdated, or
unused drugs at home. These are usually dis-
posed of via the sanitary sewer or household
trash. The magnitude of drugs disposed of by
these methods was demonstrated by a study
from the Pittsburgh Poison Center and
Children’s Hospital of Pittsburgh in
Pittsburgh, Pennsylvania, in 1996. Of 500
people surveyed, 54% disposed of medica-
tions in the solid wastes collected by their
municipality, and 35.4% ﬂushed medications
down the toilet or sink (106).
Table 3. Drugs subject to EPA hazardous waste
management requirements if discarded unused.
Chemical EPA 
Abstracts hazardous
Listed waste name Registry No. waste numbera
Chlorambucil 305-03-3 U035
Cyclophosphamide 50-18-0 U058
Daunomycin 20830-81-3 U059
Diethylstilbestrol 56-53-1 U089
Epinephrine 51-43-4 P042
Formic acid 64-18-6 U123
Gallium nitrateb 69365-72-6 D001
Lindane 58-99-9 U129
Melphalan 148-82-3 U150
Mitomycin C 50-07-7 U010
Phenacetin 62-44-2 U187
Phenol 108-95-2 U188
Reserpine 930-55-2 U180
Resorcinol 108-46-3 U201
Streptozotocin 18883-66-4 U206
Nitroglycerine 55-63-0 P081
Uracil mustard 66-75-1 U237
Warfarin, sodium saltc 81-81-248 U248
aListed hazardous waste (94). bUnlisted waste with regulated
characteristic of ignitability when drug is in concentrated form.
See Code of Federal Regulations (95). cNumber applies to parent
compound.
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Contaminated excreta. Excreta from
patients taking drugs are discharged to the
sanitary sewer and processed at POTWs or, in
areas not served by sewers, by septic systems.
Potential Environmental Impacts 
of Pharmaceutical Wastes
The potential environmental impacts of
essentially unregulated releases of pharmaceu-
tically active substances on ecosystems, human
health, and fertility is an area of increasing
concern for many biomedical scientists and
EPA (107–109). In addition to uses of phar-
maceuticals in medicine, agriculture is another
major potential source of drug contamination
in the environment. An example is the wide-
spread use of antibiotics for growth promo-
tion in livestock production (110).
Regardless of their source, all pharmaceu-
ticals are eventually disposed of, and unless
collected and destroyed by incineration or
other effective treatment processes, they are
likely to be released to the environment.
Drugs have characteristics that increase their
potential to be significant pollutants. Most
drugs are biologically active at low dose levels.
They are relatively stable under environmental
conditions, and their use is increasing rapidly
with a population that is growing and aging.
The fate and effects of drugs on the
environment are largely unknown, because
monitoring for drug contaminants in
environmental media is very limited. There
is no routine testing for pharmaceuticals in
wastewater and drinking water, and analytic
methods are either not available or deemed
not cost effective (111). The limited data
available suggest that many drugs may pre-
sent potentially significant environmental
impacts.
a) Many types of drugs are not degraded
or removed by wastewater treatment systems
or passage through soil (107,111–116).
b) Some drugs are already ubiquitous,
mobile, and persistent in the environment.
For example, cloﬁbrate, a lipid-lowering drug,
and its derivative, clofibric acid (CA), have
been found in surface water, groundwater,
and marine environments. In fact, the con-
centrations of CA found in the North Sea
and samples from other environmental
sources are found at the same levels as other
classic environmental pollutants such as
γ -hexachlorocyclohexane (115).
c) Drinking water treatment systems may
not degrade or remove drug contaminants.
Few studies of treated drinking water supplies
have been completed. However, the available
information suggests that treatment methods
may not be effective in removing drug conta-
minants. For example, in a recent sampling
survey, 100% of 64 samples of drinking water
samples collected in Berlin, Germany, con-
tained CA (117).
d ) The discharge of antibiotics with
wastewater may favor growth of multiple
antibiotic-resistant strains of bacteria and
have adverse impacts on biological wastewater
treatment processes (118–127). Antibiotics
such as the ﬂuoroquinolones may be primary
sources of genotoxicity in wastewater from
hospitals (128).
e) Potentially carcinogenic residues of
cytotoxic drugs have been found in waste-
water and drinking water (107,116,129). 
f ) Drugs known to be hormonally active
agents may act as endocrine disruptors and
are found in environmental media and drink-
ing water (107,130–132). 
Additional information on the sources,
fate, and potential impacts of drugs in the
environment is presented in the extensive
reviews by Halling-Sørensen et al. (107) and
Daughton and Ternes (108).
Trends That May Affect the 
Generation of Drug Wastes and 
Their Impacts on the Environment
Increasing allocation of research to smaller
facilities. This issue of drug waste manage-
ment in clinical research is complicated by
the trend to perform research in smaller com-
munity medical facilities. Increasingly, clini-
cal trials are being performed in community
hospitals, outpatient treatment facilities, and
doctors’ private ofﬁces, facilities that are sub-
ject to minimal waste disposal requirements.
Decreasing hospitalization time. There is
also a trend to decrease hospitalization and
increase outpatient treatment. This means
some clinical trials involve treatment of patients
in an outpatient setting where they will return
to their homes in the community within 24 hr.
Usually, no provisions have been made to
instruct patients on appropriate disposal pro-
cedures for drug-related wastes generated at
home, and no system is in place to monitor
drug disposal in the home environment. 
Increasing use of drugs for long-term ther-
apy. An example is tamoxifen citrate, a non-
steroidal compound that can act as an
antiestrogen. It is commonly used as long-
term maintenance therapy for breast cancer
patients and is being promoted as preventa-
tive therapy for women at high risk for devel-
oping breast cancer. A review of its
pharmacological properties reveals that 65%
is excreted over 2 weeks, with fecal excretion
the primary route of elimination. Although
less than 30% is excreted unchanged, most of
the metabolites are conjugates of the drug
that have activity similar to the original drug
(92). This drug and others that are promoted
for use in preventative therapy are of particu-
lar concern because they may be used by a
large population of patients over long periods.
The environmental load from drugs used in
this manner could be substantial. 
Recommendations
The subcommittee offers these recommen-
dations to address the drug disposal issues
identiﬁed in this report:
Assessment procedures for new and existing
drugs should be improved. The U.S. Food and
Drug Administration (FDA) is required under
the National Environmental Policy Act to
consider the environmental impacts of
approving a drug and biologics applications as
an integral part of its regulatory process (133).
For the following reasons the process does not
appear to ensure rigorous review of the poten-
tial environmental hazards posed by drugs.
a) The majority of drug products are
covered by categorical exclusions and other
provisions that exempt manufacturers from
having to conduct an environmental assess-
ment (134,135). This means that informa-
tion on the environmental fate and impacts
of most new pharmaceuticals will not be
available. 
b) Environmental impact assessments and
projections of concentrations in the environ-
ment are based only on approved uses of
drugs. Substantial quantities of drugs are
used for nonapproved applications. Some
estimates are that 50% of all drug sales and
up to 80% of sales of drugs used to treat
cancer patients are for off-label, or non-FDA
approved, indications (136).
c) There are no requirements for assess-
ment of impacts after drugs receive FDA
approval.
A better system is clearly needed to ensure
that the environmental hazards posed by
existing and new drugs are evaluated and that
a balance is achieved between the potentially
competing needs of expedited drug approval
and environmental impact assessment (EIA).
Exemptions from the EIA process for new
drugs should be based on screening criteria
that consider expected stability in wastewater
and drinking water treatment systems, envi-
ronmental persistence, and toxicity. When
information on potential use of a drug for
unapproved purposes is available, this should
also be considered in the EIA. Scientiﬁc data
used in reviews of proposed exemptions
should be obtained from all available sources,
including pharmaceutical manufacturers and
independent entities. 
Improved analytical techniques and moni-
toring programs for drugs in wastewater,
drinking water, and the environment are
needed. The lack of monitoring data for drugs
has severely limited the ability to determine a)
the fate and impacts of drugs on the environ-
ment, b) the removal efﬁciencies of wastewater
and drinking water treatment processes, c) the
potential for human exposures, and d) biolog-
ical effects. The high costs and lack of estab-
lished analytical methods will continue to
preclude widespread testing for the myriad
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specific drug compounds and metabolites
that may be present in environmental media.
An alternative may be to use screening tools
such as microbial toxicity assays to monitor
drinking water and wastes before they are dis-
charged or applied to the land. Positive assay
results could be used to trigger additional
testing for specific drugs or initiate more
aggressive treatment measures. Development
and implementation of these alternative
screening tests and monitoring programs
should be accelerated.
Effective technologies for removal of drugs
in water and wastewater treatment processes
need to be developed. The presence of drug
contaminants in wastewater is inevitable.
High priority should be assigned to research
and development of technologies to degrade
drugs in wastewater before it is released to the
environment, and to remove contaminants
from drinking water.
Alternative treatment technologies for
medical wastes must be evaluated. New tech-
nologies such as microwave irradiation are
now being used as alternatives to incineration
for treatment and disposal of medical wastes.
The effectiveness of these technologies in
treating drug contaminants should evaluated
before they are used for processing wastes that
may contain these contaminants.
Reinvent the regulatory framework
governing disposal. Current regulation of
most aspects of drug waste disposal is mini-
mal, fragmented, and focused on a small,
arbitrarily deﬁned list of drugs. A uniform set
of regulations should be developed for dis-
posal of all drugs. Toxicity, persistence, and
environment impacts should be primary crite-
ria for determining the drugs that are regu-
lated, not the type and size of facility from
which they are dispensed.
Improve access to disposal options.
Systems for cost-effective collection and
appropriate disposal of unused drugs from
patients, pharmacies, healthcare providers,
and facilities of all types need to be devel-
oped.
Improve awareness and training. The
research community, EPA, FDA, and phar-
maceutical manufacturers should work
together to design educational programs to
better inform investigators, healthcare
providers, and patients about the potential
environmental impacts of pharmaceutical use
and appropriate disposal methods. 
Expand the role of research facilities.
Research facilities should take a leading role
in developing and implementing environ-
mentally sound procedures for collection and
disposal of drug wastes.
Make provisions for better management
of wastes during clinical trials. All clinical tri-
als must be reviewed and approved by the
institutional review board where the trials will
be conducted. The subcommittee found no
requirement for institutional review boards to
consider waste minimization and disposal.
Protocols should ensure that both investiga-
tors and patients receive instruction on
appropriate disposal of drug-related wastes,
and provisions for return of unused drugs to
the research facility or other appropriate dis-
posal outlets should be made.
Examples of Best Practices 
General source reduction and minimization
options. In its report on selected hospital
waste streams (68), EPA identified options
for minimization of antineoplastic drug
wastes that are probably applicable to other
types of drugs as well. These are presented
here with some adaptations for research facili-
ties and additional options identified by the
subcommittee.
a) Purchase drugs in quantities according
to need—to reduce generation of wastes. 
b) Return outdated drugs to manufacturers.
c) Donate usable surplus drugs.
d) Segregate drug wastes from other
wastes.
e) Further segregate drug wastes into
treatability groups so as to minimize the
amount of wastes that require special han-
dling and disposal procedures e.g., cytotoxic
drugs, controlled substances.
f ) Dispose noncontaminated personal
protective apparatus such as gowns and other
items from drug administration procedures as
general solid waste.
g) Use spill containment and clean-up
procedures that minimize the volume of cont-
aminated materials.
Process changes for source reduction of iv
drug wastes. A project initiated by the NIH
CC Pharmacy provides a speciﬁc example of
how relatively simple changes in ordering,
production, and distribution systems can
greatly reduce generation of drug wastes. A
management team reviewed dispensing pro-
cedures and found that most of the unused iv
drug wastes could be eliminated by initiating
a new just-in-time production and delivery
system. The system automatically reorders
solutions when the nursing department docu-
ments administration of a solution. This
eliminates most of the wastes generated by
advance ordering. Other innovative source
reduction procedures identified by the team
included a) having pharmacy staff deliver
solutions to ensure proper handling during
transit to patient units and correct storage on
arrival at the units; b) purchasing premixed iv
solutions with extended shelf lives whenever
appropriate; c) mixing and activation of iv
drugs and solutions at the administration site;
and d) training of an additional pharmacy
technician so that iv solutions could be mixed
and dispensed around-the-clock.
After these procedures were put into
place, large-volume iv drug waste was reduced
from 31 to 6%, commercial premixed iv bags
returned to the pharmacy dropped from 35
to 1%, and waste of customized, small-
volume iv solutions was cut from 18 to about
8% (137).
Assured destruction of all hazardous drugs.
Research facilities should employ procedures
that assure appropriate management and
destruction of all potentially hazardous drugs
regardless of their regulatory status. Many
drugs have hazardous properties similar to reg-
ulated drugs, yet there are no regulations gov-
erning their disposal. For example, of some
120 antineoplastic drugs currently in use at
the NIH CC (138), less than 6 are regulated
as hazardous waste. NIH collects all unused
antineoplastic agents and manages them
according to the same procedures used for reg-
ulated hazardous wastes. All antineoplastic
drug wastes are incinerated as either hazardous
waste or medical waste. This practice has been
in place for many years (105,139).
Subcommittee on Radioactive
Wastes
Radioactive waste is an inevitable by-product
of society’s current use of radionuclides in
medical research, diagnosis, and treatment of
disease (140). Waste management and dis-
posal operations should be considered an
integral part of these uses. It is wrong to
regard these operations as a freestanding prac-
tice needing its own justification (141).
Biomedical research facilities should develop
a radioactive waste minimization plan to pro-
tect public health and the environment by
reducing both the volume and activities of
wastes they generate. Less waste also reduces
potential liabilities and costs, conserves dis-
posal capacity at the few operating waste dis-
posal sites, and facilitates better management
by the disposal site operator.
Classiﬁcation and Deﬁnitions
Radioactive materials exist in nature or may be
produced artificially. Regulations governing
the use of radioactive materials depend on
their origin. Source, special nuclear, and by-
product radioactive materials are regulated by
the U.S. Nuclear Regulatory Commission
(NRC) or by states approved by NRC (agree-
ment states). Any waste that contains or is con-
taminated with any of these materials is subject
to NRC regulation. Many biomedical research
institutions subject to NRC regulation will
generate low-level waste (LLW). LLW is waste
requiring disposal at a land disposal facility and
is deﬁned by the NRC as radioactive waste not
classified as high-level radioactive waste,
transuranic waste, spent nuclear fuel, or ura-
nium or thorium mill tailings or waste. LLW is
designated Class A, B, or C, depending on the
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concentration of short- and long-lived
radionuclides present in the waste. Most LLW
generated by biomedical research facilities will
fall into the category of Class A waste.
Naturally occurring or accelerator-
produced radioactive materials (commonly
referred to collectively as NARM) are not
subject to NRC regulations or included in the
deﬁnition of LLW. The generation and use of
NARM is generally left to the states. Any
waste containing or contaminated with
NARM is not regulated by the NRC.
However, these wastes still require proper
disposal under state regulations.
Characterization
Most of the LLW generated by biomedical
research facilities and hospitals falls into sev-
eral general waste streams: dry solids, organic
liquids, aqueous liquids, biological wastes,
halogenated compounds, liquid scintillation
wastes, and sealed sources (142). 
Dry solid wastes consist of contaminated
laboratory trash and apparatus, protective
clothing, towels, paper, sharps, and packaging
materials. Biomedical research facilities may
also generate contaminated solid wastes from
patient care.
Organic liquids include radioactive wastes
that may contain alcohols, ethers, aldehydes,
ketones, toluene/benzene/xylene, and other
aromatic compounds. Many of these wastes
are considered low-level mixed wastes, a cate-
gory of multihazardous wastes.
Aqueous liquids include washings from
contaminated glassware, cell culture media,
buffers, and nonhazardous reagents contami-
nated with radioactive material.
Biological wastes include animal carcasses,
human and animal tissues, bedding, excreta,
and clinical samples. Radioactive biological
wastes that are infectious are considered
multihazardous wastes.
Halogenated wastes refers to radioactive
wastes that contain regulated concentrations
of one or more halogenated organic com-
pounds such as polychlorinated biphenyls, or
chloroform. These wastes are classified as
mixed wastes, a category of multihazardous
waste, if they are coregulated by EPA as
hazardous waste.
Liquid scintillation wastes are generated
when samples containing radioactive materials
are analyzed using an organic substance which,
when excited by the ionization of the mole-
cules due to interaction with the radiation,
emits ﬂashes of light as the molecules ﬂuoresce.
These wastes may be considered mixed waste if
they contain organic solvents such as toluene
that are regulated by EPA as hazardous waste.
Sealed sources are primarily used for
instrument calibration and require special
precautions and preparation when offered for
disposal.
Assessment of the Potential for Releases
and Environmental Impacts
The total quantity and activity of radioactive
waste disposed at commercial LLW sites from
biomedical research is a very small fraction of
the amount of commercial waste generated
nationally. The National Low-Level Waste
Management Program (NLLWMP) of the
U.S. Department of Energy annually assesses
and reports on the LLW received at commer-
cial disposal (burial) sites. Five broad cate-
gories of generators of LLW are tracked in
their reports: academic, government, indus-
trial, medical, and utility. The volume of
LLW disposed by the academic and medical
categories from 1995 to 1997 ranged from
8,358 ft3 to 11,623 ft3, or 1.4–2.8% of the
total LLW volume disposed nationally. The
total radioactivity in this waste accounted for
less than 0.1% of the amount disposed dur-
ing these 3 years (143–145).
Radioactive aqueous liquid wastes con-
taining byproduct material may be discharged
to the sanitary sewer pursuant to NRC and
state regulations. The total activity released
each year is capped (146). There have been
several cases of radioactive contamination dis-
covered at sewage treatment plants, which
required remediation at considerable cost
(147,148). However, the sites requiring
remediation were primarily contaminated due
to radioactive discharges from industrial man-
ufacturing operations, not biomedical
research facilities.
Most of the radioactive materials used in
biomedical research are short-lived radionu-
clides and are used in small quantities or low
activity concentrations. Wastes containing
only short-lived radionuclides are usually held
for decay in storage on-site and then disposed
of as nonradioactive waste. Even if these
radionuclides were released from wastes with-
out decay, it is unlikely that they could pose a
signiﬁcant threat to the environment because
their half-lives are too short to allow bioaccu-
mulation and persistence. Only two long-
lived radionuclides, 14C and tritium (3H),
find significant use in research laboratories.
Neither of these isotopes is bioaccumulative.
Biomedical research facilities may also
generate gaseous wastes that result from using
volatile radioactive materials to label com-
pounds. However, based on the restrictions
imposed by the NRC and agreement states,
the potential for significant releases and
impacts on the environment from such uses is
expected to be very small.
Source Reduction Strategies
There are many opportunities for biomedical
research facilities to prevent the generation of
radioactive wastes. Source reduction approaches
employed by successful minimization programs
focus on the users of radioactive materials.
a) A waste minimization training program
should be established to ensure that all users
of radioactive materials are aware of the
importance of incorporating practices into
their work that eliminate or reduce the
amount of waste.
b) The use of nonradioactive alternatives
for procedures that employ radioactive
materials eliminates the generation of
radioactive waste and should be encouraged.
Nonradioactive tracers are now available for
many common assays and procedures that
originally used radioactive materials (149). 
c) The amount of radioactivity used in
experiments should be minimized.
Investigators should purchase only those
radioactive materials that will be used and
avoid purchasing more when vendors offer
large-quantity discounts.
d) The number of people authorized to
use radioactive materials or having access to
areas where these materials are used should be
limited. This is also useful in maintaining
exposures to radiation in accord with the as
low as reasonably achievable (ALARA) stan-
dard of the NRC (150). 
e) Segregation of waste streams in labora-
tories is essential. Equipment and materials
should be surveyed to determine if radioactive
contamination is present before they are dis-
carded as radioactive waste.
f ) The use of shorter-lived radionuclides,
with half-lives less than 120 days, allows gen-
erators to hold the waste for radioactive decay.
Wastes containing only short-lived radionu-
clides should be collected separately from
wastes containing long-lived radionuclides.
g) Gaseous wastes should be controlled at
the point of generation. The use of charcoal
ﬁltration to remove volatile radioactive mate-
rials, particularly radioiodines, is effective at
minimizing the amount of material released
to the environment via air emissions. 
Management of Wastes
Recycling, reuse, volume reduction, release to
sanitary sewer systems, direct releases to the
environment, decay-in-storage, and land dis-
posal are common components of radioactive
waste management programs at research facil-
ities. Options for reuse and recycling of
radioactive wastes are available for a few waste
streams (151,152). Many facilities compact
wastes to reduce the volume of waste that
must be shipped off-site. Industrial super-
compactors may be used by waste processing
companies to further reduce the volume of
waste before burial. Several facilities utilize
incinerators to treat radioactively contami-
nated biological wastes, liquid scintillation
vials, and dry solid wastes (153,154).
Vitriﬁcation of radioactive waste is now com-
mercially available and can achieve volume
reductions in the range of 200:1. Other waste
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treatment methods such as alkaline hydrolysis
(155), freeze drying (156), and dry distilla-
tion (157) may be performed on certain waste
types. Aqueous liquid wastes containing by-
product materials may be discharged to the
sanitary sewer, provided the facility does not
exceed limits set by the NRC (146).
Regulatory and Political Issues
Limited availability of disposal sites. Limited
access to LLW disposal facilities and rapidly
rising costs of disposal are national issues that
affect the biomedical research community.
The U.S. General Accounting Ofﬁce recently
completed a report on the status of efforts by
states and compacts to establish new disposal
facilities (158). The report states
The limited capacity of the Barnwell [SC]
facility and the lack of the successful devel-
opment of new facilities by compacts or
states raise the question of whether to
retain or abandon the compact approach.
Retaining the present system would allow
compacts and individual states to continue
to exercise substantial control over the
management and disposal of low-level
radioactive wastes but would also maintain
a system that has not provided an ample,
assured supply of future disposal capacity
[emphasis added].
Many research procedures cannot be
performed without radioactive materials, and
researchers may prefer to use them rather than
alternative reagents because the techniques are
well established and proven. Thus, future
advances in scientiﬁc knowledge may rest on
the availability of radioactive materials and the
ability to safely and economically manage
wastes resulting from work with them.
Biomedical research must not be hindered or
prevented because of the inability to provide
for disposal of radioactive wastes. The research
community must continue to work with local,
state, and Federal agencies and encourage
them to provide waste disposal capacity so
these important activities may continue.
Additional restrictions may limit disposal
of aqueous LLW. The NRC and EPA are con-
ducting a joint sewage sludge radiological sur-
vey to assess the need for additional controls
or regulations because of radioactive contami-
nation at several POTWs (159). These may
impact biomedical facilities that discharge
treated aqueous LLW to the sanitary sewer.
Examples of Best Practices
Volume reduction. Dry radioactive waste vol-
umes were reduced by over 89% using waste
shredders and compactors at the Columbia-
Presbyterian Medical Center (160). 
Reduction of off-site shipments. At
Harvard University, implementation of a
strong decay-in-storage program resulted in a
decrease from 98 to 21% in LLW shipped for
disposal off-site as a percentage of the total
amount of waste generated. The university
also uses a waste incinerator for reducing the
volume of LLW. The use of on-site incinera-
tion coupled with the decay-in-storage pro-
gram has led to reductions in the amount of
LLW shipped off-site for disposal to only
1.6% of the amount generated (161). 
On-site incineration. NIEHS has also
operated an incinerator for reducing the vol-
ume of waste from biological experiments
(154). Mass reductions achieved ranged from
91 to 97%.
Other institutional programs. Descrip-
tions of other highly successful LLW manage-
ment programs include those operated by the
Albany Medical Center (Albany, New York)
(155) and the Rockefeller University (New
York, New York) (162).
The National Low-Level Waste
Management Program of the U.S.
Department of Energy. The NLLWMP has
published many reports dealing with all
aspects of radioactive waste management sum-
marizing successful management programs.
Although is it is somewhat dated, a 1987
report provides an excellent overview of
radioactive waste management practices in
biomedical institutions (163). Current infor-
mation regarding the NLLWMP may be
obtained visiting the program’s website (164).
Subcommittee on
Multihazardous Wastes
This section discusses issues relating to man-
agement of multihazardous wastes. These
wastes are the most problematic and costly of
all of the major types of wastes generated by
research facilities.
Classiﬁcation
Multihazardous wastes. Wastes that contain
any combination of chemical, radioactive, or
biological hazard are considered multihaz-
ardous (165). Biomedical research facilities
may generate all types of multihazardous
wastes: chemical-radioactive, chemical-
biohazardous, and radioactive-biohazardous.
They are probably the only sources of
chemical-radioactive-biohazardous wastes.
Mixed wastes. A subset of multi-
hazardous wastes, mixed wastes, contain
both LLW and chemicals regulated as haz-
ardous wastes. Some wastes contain a mix-
ture of hazardous waste and radioactive
materials that is not regulated by the NRC
and thus does not meet the regulatory deﬁn-
ition of mixed waste, but requires special
consideration due to the radiological hazards
present. Mixed wastes are the most common
type of multihazardous waste generated by
research facilities and the primary focus of
this subcommittee. The hazardous chemical
portion of mixed wastes is regulated by EPA
or states authorized under RCRA. The
radioactive materials are subject to oversight
by the NRC or the states. Additionally,
mixed wastes from biomedical facilities fre-
quently contain biohazardous agents and
materials regulated as medical waste. 
Characterization
Composition. Mixed waste generated in
biomedical research institutions varies greatly
depending on the type of research being
done. The majority of mixed waste samples
are generated as organic and aqueous mix-
tures that vary in composition from a pure
radiolabeled organic compound to a crude
mixture of sludge with one or more radionu-
clides present. Additionally, wastes such as
inorganic mixtures, toxic metals, paper towels
and absorbent materials, rubber gloves,
debris, syringe needles, and hospital waste are
also generated. The most often reported
radionuclides in biomedical mixed wastes are
3H, 14C, 32P, 35S, and 125I. 
Sources and quantities generated. Mixed
waste is produced all across the United States
from processes such as medical research and
pharmaceutical and biotechnology develop-
ment. University and medical research insti-
tutions typically produce high volumes of
aqueous waste containing low levels of
radioactivity. Low to moderate waste volumes
containing higher levels of 3H and 14C are
generated from synthesis of radiolabeled com-
pounds and other research operations. 
Potential Environmental Impacts 
The potential impacts of mixed wastes on the
environment may be estimated based on
assessments of the impacts from their chemi-
cal and radiological constituents, which are
similar to those in other nonradioactive wastes
and LLW from research facilities. These
impacts were assessed in the previous subcom-
mittee reports. Based on these assessments, it
appears that mismanagement of mixed wastes
is unlikely, and accidental releases would be
likely to pose only a very low threat to human
health or the environment. 
Source Reduction Strategies
The implementation of waste minimization
programs for mixed wastes at major research
facilities has demonstrated that generation
rates can be greatly decreased. The principal
strategies employed for source reduction of
mixed wastes are similar to those for bio-
hazardous, chemical, and radioactive wastes
(162,166,167). Particular emphasis is
placed on strict adherence to segregation
requirements. By keeping radioactive and
chemical wastes separate, generation of
many types of mixed wastes can be elimi-
nated and management efforts can be
focused on unavoidable mixed wastes. The
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use of commercial laboratories to prepare
labeled compounds and reagents is also an
important strategy to reduce or eliminate gen-
eration of high-activity mixed wastes that are
extremely expensive to treat and dispose of. 
Management of Wastes
Once generated, mixed wastes must be fully
characterized and separated into common
classes based on available treatment and dis-
posal options. Most wastes can be expedi-
tiously disposed in an environmentally
benign manner. Disposal options for a few
types of mixed waste are limited or nonexis-
tent and therefore, once generated, the wastes
may require indeﬁnite on-site storage.
Recovery and recycling. Liquid scintillation
counting ﬂuids and vials and some contami-
nated nonhalogenated solvents are routinely
shipped to commercial facilities for use as fuel
supplements. At this time, recovery of the
radioactive materials or chemical components
from most liquid mixed wastes is laborious
and not practical. Only a small portion of the
solid mixed waste generated, such as contami-
nated mercury and lead, is recovered and
reused. For mixed wastes with multicurie
quantities of 3H, technology is available that
would allow for the recovery and recycling of
3H. This would eliminate the release of
radioactivity into the environment. Currently,
however, recycling opportunities are not avail-
able because of regulatory issues and the lack
of commercial recovery facilities.
Treatment and disposal. The treatment
objective for multihazardous wastes is reduc-
tion to a waste that presents a single hazard,
which can then be managed as a chemical,
radioactive, or medical waste. The sequence
of treatment methods should be according to
the degree of risk posed by the various haz-
ardous constituents (165). Examples of cur-
rently available disposal options for treatment
and disposal include a) storage of wastes con-
taining short half-life radionuclides for decay.
The waste is held until the radioactivity has
decayed, and the remaining hazardous chemi-
cal waste is disposed using an approved
RCRA facility; b) on-site treatment of haz-
ardous chemical constiuents where regula-
tions and permitting requirements have been
met; c) treatment or recycling and disposal at
a commercial EPA-permitted/NRC-licensed
facility using a thermal process (energy recov-
ery or incineration); d) land burial of treated
waste residues in approved facilities; and e)
disposal to a sanitary sewer system, e.g.,
wastes generated from human clinical and
diagnostic studies.
Long-term on-site storage. For wastes con-
taining long half-lived radionuclides and
those for which there are limited or no dis-
posal options, indefinite on-site storage may
be required. 
Regulatory Issues
Management of multihazardous wastes is
complicated by an array of Federal, state, and
local requirements that may be inconsistent
with the relative risk of each hazardous con-
stituent in the waste. The current regulatory
framework for mixed wastes is illustrative.
Overview of existing mixed waste
regulations. Once generated, mixed waste
must be transported, stored, treated, and dis-
posed in compliance with the multiple
statutes and regulations of the DOT, EPA,
NRC, and state and local governments. EPA
requires that a RCRA permit be obtained to
treat or store waste on site. However, most
research organizations elect not to obtain one
because of the high regulatory burden associ-
ated with acquiring and complying with the
permit. Consequently, many institutions have
only limited treatment and storage options
available for managing and disposing of these
wastes. To alleviate some of the problem,
EPA has established a relaxed enforcement
policy that allows generators to indefinitely
store wastes for which no treatment or dis-
posal capacity currently exists (168).
The NRC’s role in regulating mixed waste
is to assure that safe radiation practices are
maintained. For land burial of radioactive waste
containing biohazardous materials, the NRC
requires that the material ﬁrst be sterilized to
reduce the potential hazards of these materials
(169). The commission’s regulations also
require that a licensed facility monitor efﬂuent
releases and maintain them to be ALARA.
States have an important authority for
protecting the public from the potential haz-
ards associated with mixed waste, and many
are authorized or “agreement states” responsi-
ble for inspection, enforcement, and licensing
responsibilities for users of hazardous chemi-
cals and radioactive materials. Some states are
authorized to issue permits for waste treat-
ment; however, they may impose additional
requirements or constraints. 
Regulatory impediments to effective
management. EPA policies and regulations
intended for industrial-scale volumes of haz-
ardous waste place enormous economic and
regulatory burdens on small-volume mixed
waste generators. Additionally, oversight by
multiple regulating agencies further increases
the management problem. Currently, the
regulations do not appropriately consider the
burden relative to a) the variety and small
volumes of mixed wastes; b) the prohibitively
high costs associated with management and
disposal; c) the redundancies and inconsis-
tencies that result from oversight by multiple
regulatory agencies; and d) the lack of flexi-
bility to allow best practices to be used for
treatment and disposal of these wastes.
Therefore, research institutions are
required to expend an enormous and costly
effort to segregate and track thousands of small
volume waste streams to comply with the regu-
lations (170,171). Additionally, because of
these impacts, many laboratories have placed
restrictions on the generation of mixed waste
and require investigators to develop alternative
research methods and procedures that may not
be as effective as isotopic methods. 
Many of the problems confronting
research facilities in management of mixed
waste result from the current dual (EPA/NRC)
regulatory framework. EPA recently developed
a comprehensive proposal to reduce burdens
associated with this framework (172).
Examples of Best Practices
The NIH Mixed Waste Minimization
Program. Proper management and waste min-
imization efforts have demonstrated that a
large portion of mixed waste currently being
generated can be reduced or eliminated (170).
At NIH, generation rates were decreased sig-
nificantly, even though the number of
research studies was rapidly increasing.
Ultraviolet peroxidation treatment of
aqueous mixed wastes. A modiﬁed version of a
commercially available ultraviolet peroxida-
tion (UVP) treatment system has been devel-
oped and used to degrade hazardous organic
compounds in high-volume aqueous mixed
waste streams from biomedical research (170).
UVP uses hydrogen peroxide and ultraviolet
light to oxidize organic compounds to carbon
dioxide and water. The system has a demon-
strated removal efficiency for a number of
volatile and semivolatile compounds in excess
of 99.99%. No hazardous air emissions or
residues are produced by the treatment
process. Treated wastewater from the UVP
system can be discharged to the sanitary sewer.
Catalytic oxidation treatment process for
wastes containing higher activity. A catalytic
chemical oxidation process has been exten-
sively studied for the on-site treatment of
mixed wastes containing hazardous chemicals
and high levels of 3H and 14C radionuclides
(173). Both organic and aqueous mixtures
can be accommodated without sample pre-
treatment, and destruction and removal efﬁ-
ciencies of 99.999–99.99999% are achieved
for most organic substances. The radioactive
waste products from the process, either triti-
ated water or 14C carbon dioxide are recov-
ered using a simple trapping system without
release to the environment. 
Subcommittee on Solid
Wastes and Recycling
Characterization of Wastes from
Research Facilities
Biomedical research facilities generate signiﬁ-
cant quantities of general solid wastes. Wastes
in this category are considered nonhazardous;
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they generally will not cause or significantly
contribute to an increase in serious irre-
versible or incapacitating reversible illness or
pose a substantial present or potential hazard
to human health, safety, or welfare. When
properly managed, they should pose no sig-
nificant adverse effects on the environment.
The characterization of general solid wastes
generated from biomedical research facilities
is often similar to municipal solid waste
(MSW) (174,175). Additionally, biomedical
facilities may generate some forms of solid
wastes that are not considered MSW, such as
ash from medical waste incineration and ani-
mal bedding.
Conventional solid wastes from biomedical
research facilities are generally managed in the
same way as similar wastes from other sources.
However, some aspects of research facility
operations affect the characterization of the
wastes that are generated and their manage-
ment requirements. It is often necessary to
modify the solid waste source reduction, recy-
cling, collection, and disposal strategies that
are in general use for applications at research
facilities. First, it is of paramount importance
that all necessary precautions are taken to
ensure strict segregation of hazardous wastes
and items perceived as hazardous from wastes
that will be disposed of as general waste. In
most laboratories and other research facilities,
hazardous materials are used and disposed of
in close proximity to nonhazardous materials.
This raises the potential for inadvertent min-
gling of hazardous and nonhazardous wastes
that can have very serious consequences. 
Second, characteristics of the general solid
waste streams from many facilities complicate
development of recycling programs and limit
the types of wastes that can be reused or recy-
cled in an efﬁcient and cost-effective manner.
Reuse and Recycling Options
The preferred disposition of unwanted items
is transferring them to others for reuse or
other uses that do not require reprocessing.
Reuse, as compared to reclamation of materi-
als from waste (recycling), conserves the most
value, usually requires the least amount of
energy, and generates less pollution and
secondary waste. 
Many research facilities have developed
successful solid waste recycling programs, par-
ticularly for commodities such as aluminum,
cardboard, paper, and glass that are com-
monly recovered from MSW. Although the
prices paid for such materials are usually not a
major source of income to facilities, diversion
of these materials from the solid waste stream
eliminates disposal charges, which may be sig-
niﬁcant. Recycling of materials from BRW is
more problematic and not widely practiced:
a) Laboratories and other biomedical
research areas typically generate quantities of
recyclable materials that may not sufﬁcient to
justify the management burdens, space, and
costs associated with development and opera-
tion of segregated collection, storage, and
shipping systems.
b) Recycling facilities may not accept
small lots of recyclable materials because of
high overhead costs associated with handling,
quality control, reprocessing, and accounting.
For example, waste streams from laboratories
and photoprocessing operations may contain
recoverable precious metals such as silver,
gold, platinum, and osmium. Even though
these are very valuable materials, the costs of
transporting wastes to reclamation facilities,
assays, record keeping, and processing small
quantities of these wastes often far exceed
their recovery value.
c) Some potentially recyclable materials
are unique to research facilities or have char-
acteristics that severely limit their market
value. For example, flint glass typically used
in beverage containers is relatively easy to
sort, melt, and reprocess into usable products.
There are commercial markets for it and it is
widely recycled. However, laboratory glass-
ware and some reagent bottles are made of
borosilicate glass that has a very high melting
point and may not meet the acceptance speci-
ﬁcations of recycling facilities.
d) Plastics are another example of materi-
als that are commonly recovered from MSW
but usually not good candidates for recycling
from laboratory waste streams. Plastic items
have recovery value if they are sorted by resin
content and made from resins that are widely
used in commercial products. The plastics
found in MSW consist of relatively few
resins, and the resin content of most com-
mon items such as beverage containers is
readily identified by numbered symbols
embossed on the container. This facilitates
sorting and recovery. In contrast, plastics
used in items for laboratory and medical
applications are made from a wider variety of
resins, and these are often not identified on
the items. Some resins that ﬁnd use in labo-
ratory ware such as tetrafluoroethylene have
few if any recycling outlets.
Waste streams that are the best candi-
dates for recycling have established commer-
cial markets, are generated in high volumes,
and consist of relatively pure materials free of
contaminants that interfere with the recy-
cling process. For optimal recovery value,
recyclable wastes must be segregated from
other materials, collected, and shipped in
accordance with the specifications of the
receiving facility. Receiving facilities usually
have a low tolerance for contaminants. Small
amounts of contaminants may result in the
rejection of large lots of recyclable materials
or severe downgrading prices paid for these
materials.
Examples of Best Practices
MERCI—An exemplary institutional
program for solid waste reduction and recov-
ery of valuable materials. A program con-
ceived at the University of Virginia in
Charlottesville, Virginia, titled Medical
Equipment Recovery of Clean Inventory
(MERCI) was developed to ensure efficient
waste stream management and to affect a
global reduction in solid waste generation and
disposal costs (176). A major emphasis of the
program was to systematically divert clean,
usable materials, or “gold wastes,” from incin-
eration to charitable organizations or back
into the university’s medical center and
research laboratories. Examples of supplies
diverted from operating room wastes for reuse
in biomedical research laboratories include
the following:
a) Gowns that could be used as clean pro-
tective clothing for workers in research labo-
ratories. These were found to be of better
quality than cover gowns available for pur-
chase, and they were provided at no cost to
the laboratories by the MERCI program. 
b) Surgical drapes for use as lab bench top
covers.
c) Paper operating room towels used for
linings on trays, counters, and other surfaces.
d) Numerous examples of specialized
items salvaged from operating rooms that
research laboratories use in their work, e.g.,
needle counters. 
Eight years following its inception, the
program has evolved into a total integrated
waste management system, capturing over 73
tons of medical supplies for use in research
laboratories or donation to charitable organi-
zations. Ultimately, these data suggest a sav-
ings of 15.5 million dollars in supplies that
would have been incinerated. Waste stream
audit information stemming from this pro-
gram was also used to streamline the use of
medical supplies at the university.
Recycling program at NIEHS. The solid
waste management program operated on the
campus of NIEHS provides an example of a
comprehensive solid waste recycling program
at a major biomedical research facility. Large
quantities of materials destined for a landﬁll
or incineration are now being diverted by
source reduction and recycling initiatives.
Source reduction activities at NIEHS include
the following:
Redistribution or donation of surplus mate-
rials. Surplus materials are ﬁrst made available
to all employees at a waste-exchange area
located on the campus. Materials and supplies
that are not claimed there are often donated
to local community colleges and schools.
Paperless reports. Research studies result in
the production of many voluminous reports.
Instead of distributing paper copies to inter-
ested parties, the facility now sends electronic
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copies, saving significant amounts of paper
and postage. Many studies required 12 or
more copies of reports, typically 200–300
pages long. These are now distributed
electronically without paper. 
Computer recycling. Computers and old
equipment outdated for NIEHS use yet ser-
viceable are made available to local schools,
colleges, and universities.
Major recyclable general solid wastes
streams at NIEHS include white paper, ﬁber
paper, glossy paper, newspaper, aluminum
beverage cans, steel “tin” cans, consumer plas-
tics (beverage bottles), and glass. Table 4 lists
the types of materials and amounts recycled
on the NIEHS campus since February 1993.
The total amount of material recycled is
approaching 1,000 metric tons. The facility
currently recovers about 25% of its solid
waste stream for recycling.
Subcommittee on Training
Training is one of the most critical components
of effective waste management programs and
is mandatory for all personnel involved in
generation, handling, and management of
wastes in biomedical research facilities. A
clear understanding of all regulatory require-
ments, job responsibilities, and institutional
procedures for waste minimization and man-
agement is crucial for ensuring the facility’s
regulatory compliance and protection of
health and safety, research resources, and the
environment. Adoption of good laboratory
waste practices also carries with it a tremen-
dous potential for designing pollution out of
future industrial processes (177). This is a
concept that can also be applied to biomed-
ical research facilities and the products of
their research that may ultimately be used on
a large scale in medicine. Well-designed waste
management training programs not only
teach institutional waste management prac-
tices but also improve awareness of general
pollution prevention concepts. Such training
programs can help create a new generation of
investigators, facility operators, healthcare
workers, and patients that is more environ-
mentally conscious and informed.
Overview of Regulatory Requirements
for Training
Federal, state, and local governmental
agencies, as well as numerous accreditation
organizations, regulate biomedical research
and healthcare institutions and stipulate
training requirements. This section provides
an overview of training required by Federal
agencies. 
U.S. Environmental Protection Agency.
Training requirements for hazardous waste
generators are specified in EPA regulations
(178,179). The training program must
include instruction on all aspects of
hazardous waste management relevant to the
position in which personnel are employed,
including contingency plan implementation.
Topics that should be in the curriculum
include a) requirements of RCRA and applic-
able state and local regulations, b) waste mini-
mization techniques, c) hazardous waste
identiﬁcation and classiﬁcation, d) hazardous
waste accumulation and storage procedures,
e) record keeping and reporting requirements,
f ) emergency response procedures and sys-
tems, g) potential liabilities associated with
mismanagement of wastes, and h) employees
who respond to hazardous substance releases
other than those classiﬁed as incidental spills
must also be trained in accordance with the
hazardous waste operations (HAZWOPER)
standard (180). 
For all employees, training records must
be kept on ﬁle and include speciﬁc documen-
tation (179).
U.S. Nuclear Regulatory Commission. The
NRC promulgates training regulations for
individuals who work in or frequent areas
where radioactive materials or wastes are used
or stored (181). Laboratory workers who work
in these restricted areas must receive informa-
tion and training on the applicable provisions
of NRC regulations and licenses for the pro-
tection of personnel from exposure to radioac-
tive materials, including a) information on the
storage, transfer, and use of radiation, radioac-
tive materials, and waste; b) health protection
problems associated with exposure to radia-
tion and/or radioactive materials; c) precau-
tions or procedures to follow to minimize
exposure; d) purpose and function of protec-
tive devices; e) responsibilities and procedures
for promptly reporting any condition that
may cause a violation of NRC regulations and
licenses or unnecessary exposure to radioactive
material; f ) procedures for responding to
warnings made in the event of any unusual
occurrence or malfunction that may involve
exposure to radiation and/or radioactive mate-
rials such as spills of radioactive materials; and
g) radiation exposure reports, which workers
may request  (182).
Occupational Safety and Health
Administration. The Occupational Safety
and Health Administration (OSHA) pro-
mulgates health and safety general and spe-
cific standards, many of which include
training requirements applicable to waste
management activities in research facilities.
Laboratory workers exposed to hazardous
materials and wastes in the workplace must
be trained in accordance with the OSHA
Hazard Communication (HAZCOM)
Standard (183). The Bloodborne Pathogens
Standard (184) deals with regulated medical
waste and prevention of occupational expo-
sures to biohazardous agents and stipulates
speciﬁc training requirements. Other OSHA
requirements of general application such as
standards for the use of personal protective
equipment (PPE) include training require-
ments that may affect personnel required to
use PPE in waste management operations.
In some circumstances, laboratory work-
ers may be required to participate in emer-
gency responses to hazardous materials
incidents or participate in operations at waste
storage, treatment, and disposal facilities.
Under OSHA regulations, such personnel are
designated HAZWOPER employees and
must complete a program of specific health
and safety training and periodic refresher
courses. NIEHS sponsored a workshop that
established minimum criteria for determining
the quality of worker health and safety train-
ing programs necessary to meet the training
requirements speciﬁed in these HAZWOPER
training standards. The results of this work-
shop were adopted by OSHA as Appendix E
of the regulation (185). 
U.S. Department of Transportation. The
DOT regulates the packaging, labeling, trans-
portation, and shipping of wastes that are
defined as hazardous materials (HAZMAT).
All employees who package, ship, receive,
unload, inspect, or certify HAZMAT ship-
ments are designated HAZMAT employees
and must receive DOT training. The training
must include general awareness and familiar-
ization with hazardous materials, safety pre-
cautions, and function-specific training that
addresses DOT regulatory requirements as
applied to an employee’s job responsibilities.
A record of current training inclusive of
the preceding 3 years must be kept on ﬁle for
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Table 4. Materials recycled at the NIEHS since February
1993.
Recovered material Amount (kg) % of total
White paper 307,386 32.5
Corrugated cardboard 175,190 18.5
Fiber paper 161,725 17.1
Magazines 137,871 14.6
Newspaper 60,468 6.4
Wood pallets 37,514 4.0
Tyvec garmentsa 23,881 2.5
Aluminum beverage cans 8,250 0.9
Wastes suitable for  8,812 0.9
vermicompostinga
Phone books  8,135 0.9
Consumer plastic and glass  6,254 0.7
containers
Molded polystyrene foam  2,302 0.2
and “peanuts”a
Polypropylene pipette tip boxes 2159 0.2
Steel cans 1,282 0.1
Other (books, ﬁlm, plastic lab  3,872 0.4
ware, shredded paper, 3-ring 
binders,a plastic drums,a
animal boxes,a reagent 
bottles,a ice bagsa)
Totals 944,471 100.0
aItems recovered by employees independent of the NIEHS
recycling contract.
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each HAZMAT employee. Training records
must include speciﬁc documentation (186).
Elements of Successful Training
Programs
Waste minimization training programs
focused on laboratory and healthcare person-
nel have been one of the most effective strate-
gies for affecting significant reductions in
waste generation at biomedical facilities.
Effective training programs not only provide
instruction on proper waste management
practices but also encourage employee coop-
eration by improving awareness of the costs
and impacts of waste disposal, and how the
actions of each employee contribute to meet-
ing the waste reduction goals of the entire
institution. 
Delivery of training. Classes and training
materials must be designed to meet the spe-
cial needs of biomedical facility operations.
They should be a) tailored to meet specific
needs and educational levels, which vary
widely among investigators, students, facility
support personnel, and patients who make up
the audience; b) flexible to accommodate
rapid change; c) easy to use, schedule, and
update; and d) multilingual and multicul-
tural as determined by the composition of the
audience.
Frequency of training. Training should
be provided to all new employees and on a
periodic basis as refresher or update service
for existing employees. Additional training
may be necessary, e.g., when a researcher
moves to a new laboratory with different
technical responsibilities or whenever sub-
stantial changes in procedures occur that
affect waste generation or management. The
initial training for new employees should be
formal and can be combined with training
required for radiation safety, general safety,
or other research programs. Follow-up train-
ing can be completed during staff meetings
or regularly scheduled safety meetings. Such
training sessions also can be a good time to
solicit waste minimization ideas from staff or
to identify team members who can assist in
implementing specific waste minimization
opportunities.
Use of advanced training technologies.
The development and application of
advanced training technologies (ATT) has
expanded over recent years and is expected to
expand further. Computer-based training,
Internet or web-based training, distance
learning, teleconferencing, multimedia, and
courseware applications for use in training
programs are not only emerging, but many
are well established. Environmental health
and safety departments at many academic and
research institutions use web sites for provid-
ing waste management guidance and training
to students, faculty members, and researchers.
In some cases, training can be completed
entirely online. NIEHS conducted a technical
workshop on ATT 20–21 April 1999 (187).
This workshop focused on the application of
computer and web-based training methods
for safety and health training programs. The
ﬁnal report gives excellent background infor-
mation on ATT methodologies. 
Continuous program evaluation and
improvement. All training program plans
should incorporate provisions for perfor-
mance measurement, feedback, and continu-
ous improvement. Successful programs must
be able to demonstrate that what was taught
is being practiced at the work site. This is an
important part of the facility evaluation
processes used by surveyors such as those
from the Joint Committee on Accreditation
of Healthcare Organizations (JCAHO)
(188,189).
Recommendations
Eliminate redundant training requirements.
Some of the training and documentation
requirements of the various regulatory agen-
cies are redundant and should be consoli-
dated or eliminated. 
Train students at all educational levels.
Curricula for students in college level bio-
medical disciplines should include instruction
on pollution prevention and waste manage-
ment. Additionally, programs should be
developed to reach students in the early years
of their education from kindergarten through
high school. 
Provide outpatient training. Programs
must be developed for addressing training
needs of audiences outside of the regulated
community, such as patients living at home.
Home-generated wastes must be properly
managed to minimize risks to the environ-
ment, solid waste workers, and the patients
themselves. 
Examples of Best Practices
The subcommittee found that many biomed-
ical institutions and organizations have devel-
oped innovative and highly effective
programs, standards, courses, guidance docu-
ments, and other materials for waste manage-
ment training. Some of these best practices
are described below. 
NIH Waste Disposal Guide. All research
laboratories at NIH receive summary infor-
mation on segregation, packaging, and dis-
posal of various types of wastes in a pamphlet
that summarizes proper segregation, labeling,
and disposal practices (190). The pamphlet is
published in a calendar format that can be
mounted on the wall. Lift-up pages for each
“month” provide a ready-reference source of
information on segregation and management
methods for various types of waste.
Telephone numbers to obtain technical
assistance, collection containers, waste
removal, and other services are also pro-
vided. This guide is also available on the
Internet (191).
NIH mixed waste training videos. NIH
produced two videos to augment its mixed
waste training program. The first video is
titled “Mixed Waste: A Major Issue in
Biomedical Research” (192). It provides an
overview of mixed waste management issues
and includes presentations by several NIH
investigators describing innovative strategies
they have developed to minimize mixed waste
in their laboratories. A second ﬁlm was pro-
duced in 1995 to review concepts presented
in the ﬁrst ﬁlm and to provide an update on
new mixed waste management issues (193).
The Medical Waste Institute—
Transportation of Regulated Medical Waste
Compliance Assistance Document. The
Medical Waste Institute has prepared a com-
pliance guidance document for the trans-
portation of regulated medical waste (194).
This document is concise, easy to read, and
provides an excellent summary of the DOT
requirements for packaging, identification,
and transportation of RMW.
Association of Operating Room Nurses
guidance document. The Association of
Operating Room Nurses (AORN) issued its
“Recommended Practices for Environmental
Responsibility in the Practice Setting” in
October 1993. This guidance document rec-
ommends practices for waste management to
reduce the risk of infection, ensure regulatory
compliance and resource conservation, and
promote cost containment (195). Many orga-
nizations have adopted the waste handling
guidelines of AORN. The guidance docu-
ment is also useful as a reference for prepara-
tion of training courses.
Joint Commission on Accreditation of
Healthcare Organizations standard. The
JCAHO has included proper waste manage-
ment procedures as part of their accreditation
criteria. Their “Standards for Hazardous
Materials and Waste” afﬁrms the importance
of training: “As with the entire JCACO pro-
gram, proper procedures and employee train-
ing are key factors, as is evaluating actions for
their effectiveness” (196). 
Summary Findings
This section summarizes the findings of the
subcommittees as they relate to the general
issues addressed by the conference.
Potential Impacts of Biomedical
Research Wastes on the Environment
All information available to the committee
suggests that the potential for significant
impacts on the general environment from
wastes generated by biomedical research
facilities is low.
 108S6.  11/30/00 11:24 AM  Page 972    (Black plate)MINIMIZATION AND MANAGEMENT OF WASTES FROM BIOMEDICAL RESEARCH
a) For all waste streams studied, the con-
tribution of research facilities to the total
amounts of wastes generated in the United
States is very small relative to other sectors in
the economy. 
b) Hazardous substances used by research
facilities are stored and handled in small con-
tainers and apparatus, and points of use for
these substances are usually scattered among
the numerous separate laboratories and build-
ings. The probability of a catastrophic event
resulting in the uncontrolled release of large
quantities of hazardous substances is low.
c) Larger quantities of hazardous sub-
stances may be processed and stored at cen-
tralized waste collection, processing, and
storage areas located on these facilities.
However, requirements for containment,
monitoring, and control of wastes are signiﬁ-
cantly more stringent than those imposed on
substances with similar or greater hazards that
are not waste. Hazardous wastes are also sub-
ject to storage time and inventory limits that
do not apply to hazardous substances that are
not wastes.
d) Because the quantities of hazardous
substances in use and disposed of by research
facilities are usually small, uncontrolled
releases would be likely to impact only local-
ized areas, not the general environment. The
specific characteristics and management
requirements for the various types of haz-
ardous constituents commonly present in
BRW tend to reduce the potential for releases
and adverse impacts even if they are released.
e) Regulations require use of final waste
treatment and disposal technologies that are
protective of the environment.
f ) Increasing implementation of pollu-
tion prevention and waste minimization pro-
grams by research facilities is reducing the
amounts of waste generated by research pro-
cedures and the environmental toxicity of
unavoidable wastes.
An exception to this assessment of a low
potential for impacts are wastes containing
antibiotics, antineoplastic agents, hormones,
and other unregulated drugs that are released
and may be persistent and toxic in the envi-
ronment. Although the amounts of these sub-
stances disposed of by research facilities are
miniscule in comparison with the total
amounts used and disposed of by society,
they are arguably the products of biomedical
research and thus should be of concern. 
Regulatory Issues Affecting Waste
Minimization and Management
Impacts on research facilities. Virtually all
aspects of waste management are governed by
a complex array of Federal, state and local
laws, regulations, and permit requirements.
Additionally, research facilities may also be
subject to requirements imposed by
nongovernmental agencies such as the
American Association for Accreditation of
Laboratory Animal Care and multiple agen-
cies concerned with safety and the quality of
medical care (197). The poor fit of many
waste management regulations to the opera-
tions of laboratories is well known. Much of
this problem stems from the fact that the cur-
rent regulatory framework was promulgated
to control wastes from manufacturing and
other large-scale sources of waste. Laboratories
and research facilities have many unique
characteristics that differ significantly from
these sources (Table 5). These differences
greatly influence the characterization of
wastes and how they can be most efficiently
controlled and regulated. Regulatory agencies
have only recently begun to understand the
importance of these differences in dealing
with compliance issues (199).
Burdens attributed to the misfit regula-
tions on research facilities were identified as
major issues by this committee and have
been reported by others for some time. (For
this discussion, regulatory requirements are
referred to as burdensome if they could be
made more efficient without diminishing
the intended level of protection for the
environment.)
The most burdensome regulations on
research facilities are those associated with haz-
ardous waste. A planning group of the
National Research Council recognized that
there were problems with hazardous waste reg-
ulations as early as 1981, shortly after adoption
of the Federal regulations by EPA (200).
Similar burdens from state hazardous waste
regulations have also been reported (201). 
Recommendations for regulatory reform
have been repeatedly made by the National
Research Council, the American Chemical
Society, and others for years. Until recently
there was little action on these recommenda-
tions, as regulatory agencies gave priority in
their regulatory agendas to improving control
of large sources of waste and pollution. Now
several initiatives are underway that may lead
to signiﬁcant reductions in unnecessary regu-
latory burdens on research operations.
Examples include the following:
a) The New England Laboratory XL
Project, a collaborative 4-year pilot project
between three academic institutions
and EPA Region I to devise a flexible,
performance-based system for managing lab-
oratory waste (202).
b) A collaborative project by the Howard
Hughes Medical Institute in Chevy Chase,
Maryland, titled “Managing Hazardous
Wastes in Academic Research Institutions”
(203). The project has 10 participating acade-
mic research institutions working with offi-
cials from EPA, state regulatory agencies, and
the scientific community to develop and
demonstrate best practices for managing
hazardous wastes and a regulatory model for
implementation by Federal and state agencies.
An initiative undertaken by NIH to
improve the effectiveness and efﬁciency of its
overall research mission by reducing regula-
tory burdens experienced by the research
community. The initiative was requested by
the House Committee on Appropriations in
its report on the FY 1998 budget. Hazardous
waste management regulations were one of
the ﬁve areas of investigation that comprised
the initial focus of the effort (204). 
Regulations proposed by EPA to reduce
burdens associated with dual regulation of
mixed wastes (172).
The Department of Toxic Substances
Control of the California Environmental
Protection Agency convened a task force to
make recommendations for reform of haz-
ardous waste regulations affecting laborato-
ries. A bill adopting recommendations of the
task force was passed by the California
Assembly (205).
Impacts on applications of research. An
issue that has received little attention is the
potential impact of burdensome waste regu-
lations on the applications of research in
medicine. New diagnostic and therapeutic
procedures developed through the research
enterprise will undoubtedly result in the
generation of new types of wastes that are
problematic to manage under the present
regulatory framework. As these procedures
are approved and applied in medicine, the
tasks of managing the resulting wastes will
have to be assumed by hospitals and other
healthcare facilities. These facilities may be
reluctant or unable to perform procedures
that generate wastes that are very costly or
difficult to manage, or may expose them to
serious regulatory compliance problems. 
Here is an example of such a situation.
Newly developed perfusion chemotherapy
procedures have been developed that have the
potential to significantly improve treatment
outcomes in melanomas and other forms of
cancer that previously had very low survival
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Table 5. Comparison of biomedical research and manu-
facturing facility operations.a
Manu-
Characteristic facturing Research
Number of chemicals in use Low High
Quantities of hazardous chemicals High Low
Likelihood of creating new  Low High
substances
Use of biohazardous agents None High
Use of radioactive materials Low High
Activity of radioactive materials  High Low
used
Variability in operations Low High
Staff education level Low High
Centralized management High Low
aData adapted from Priznar (198).
 108S6.  11/29/00 5:41 PM  Page 973    (Black plate)RAU ET AL.
974 VOLUME 108 | SUPPLEMENT 6 | December 2000 • Environmental Health Perspectives
rates with all other available treatment
regimes (206–210). The procedures allow
isolation and regional treatment of the liver,
other organs, and limbs, using anticancer
agents in concentrations that cannot be toler-
ated systemically. Radioactive tracers (usually
131I) are used to monitor the procedure and
ensure that blood from the region being
treated does not enter the general circulation.
Body fluids and solid wastes contaminated
with cytotoxic drugs and radioactive materials
are generated by the procedure. These multi-
hazardous wastes may be subject to concur-
rent regulation as medical waste, hazardous
waste, and radioactive waste. The usual pro-
cessing scheme for these wastes is to store
them in a frozen state for several months
until the radioactive material has decayed
and then manage them as nonradioactive
wastes. Most hospitals probably are not
equipped to manage and store this type of
waste. In any case, if the waste were regulated
as hazardous in their state, they would proba-
bly be prohibited from storing it because
storage over 90 days generally requires a
RCRA storage permit. NRC regulations
would prohibit release of the undecayed
waste to hazardous waste or medical waste
facilities not licensed to accept radioactive
materials. Even after decay, disposal of the
resulting nonradioactive waste could be
problematic. Most chemical waste facilities
will not accept regulated medical waste, and
medical waste facilities are not permitted to
accept hazardous wastes. In short, there may
be no legal options for storing or disposing of
the waste from perfusion procedures.
Status of Waste Minimization Programs
in Research Facilities
Program expansion. Highly successful waste
minimization programs are being imple-
mented at a number of major research facil-
ities. Over 90% of laboratories in a recent
survey were engaged in waste minimization
(211). This trend mirrors the increasing
emphasis on pollution prevention and the
shift from waste management to materials
management that is occurring in hospitals
and healthcare facilities (212). Programs at
research facilities most commonly include
initiatives to encourage increased recycling
of general solid wastes and source reduction
efforts aimed at reducing generation of haz-
ardous and radioactive wastes that have high
management costs or limited disposal
options.
Key elements of successful programs. The
most successful minimization programs
include three key elements: support of top
management, emphasis on training of investi-
gators on source reduction techniques, and a
system to prioritize waste streams for focused
minimization effort.
Compatibility of minimization programs
with research. No conflicts between mini-
mization initiatives and the needs of research
were reported to the committee. Investigators
are generally supportive and cooperative once
a) they understand the intent of these initia-
tives and how their actions relate to program
goals, and b) access to information on speciﬁc
methods for reducing waste is provided.
In planning minimization programs, their
impacts on the research mission must be care-
fully considered. Minimization guidance pro-
vided to investigators should be voluntary.
Setting arbitrary quantitative goals for reduc-
tion of waste, a common practice in industry,
should be avoided. Alternative materials and
research methods recommended to meet
minimization objectives must compare favor-
ably with established methods. In some cases,
it may be not be feasible to change materials
and methods that are the basis of validated
research. Changes may also require lengthy
regulatory approval processes or new equip-
ment, which may not be available. 
In some situations, strategies primarily
intended to reduce use of hazardous materials
and waste generation may have side benefits
in increased scientiﬁc productivity. An exam-
ple of this is the use of chemiluminescent
reagents and other alternatives to radioactive
materials. These alternatives offer several
major beneﬁts from the standpoint of scien-
tific productivity, including greater stability
of reagents, cost savings in procurement and
storage of components, and reduced security
and training requirements. Over the long
term, development of novel nonradioactive
approaches may lead to wholly new scientiﬁc
and medical technologies that may have
broad societal impact (206).
Results of minimization programs.
Implementation of minimization programs at
research facilities has resulted in significant
reductions in waste generation, even at facili-
ties such as NIH that have rapidly expanding
research programs. Substantial cost savings
have also been reported. Although only a
small number of respondents to the survey by
Leonard and Reinhardt (204) had data on net
savings from laboratory waste minimization
efforts, the range reported per laboratory
facility was from $10,000 to $135,000 annu-
ally. Reductions in mixed waste generation
achieved by the minimization program estab-
lished by NIH have avoided disposal costs of
several million dollars in the last 5 years.
These findings, while encouraging, also
underscore the need for institutions to
improve documentation of laboratory waste
minimization programs and their associated
cost savings. Not only will this pass on valu-
able information to other institutions, but it
also allows for better planning and setting of
priorities for waste minimization programs.
Trends and the Future of Waste
Management 
Influence of research trends. Biomedical
research is a highly dynamic endeavor in both
its direction and methods. Changes in the
focus of investigation and the technologies
used to conduct research occur rapidly. In
recent years, most of these changes have
resulted in significant reductions in the vol-
umes, composition, and environmental haz-
ards posed by research wastes. Some recent
examples:
Less use of highly reactive chemicals. The
general trend in research emphasis away from
medicinal chemistry and toward molecular
biology has significantly decreased use and
disposal of highly reactive chemical com-
pounds used in synthesis of investigational
drugs.
Improved liquid scintillation counting
methods. For many years, liquid scintillation
counting (LSC) was one of the most widely
used analytic methods in biomedical research,
and LSC wastes have been a major and prob-
lematic component of radioactive waste
streams. LSC produces numerous small vials
containing spent counting ﬂuids that used to
be predominantly composed of a hazardous
organic solvent such as xylene, toluene, or
pseudocumene contaminated with radioactive
materials. Counting ﬂuids were subsequently
developed that do not contain hazardous sol-
vents (214), and these can now be used for
most counting applications. There have also
been changes in counting technology that
allow counting to be performed with reduced
generation of wastes. These include the use of
smaller-volume LSC vials (215) and dry
counting methods (216) that can eliminate
LSC wastes. The impact of these changes in
LSC technology has been dramatic. In 1979,
NIH generated approximately 2,000 55-gal
drums of LSC vials for shipment to off-site
recycling and disposal facilities (170).
Generation has declined continuously since
then (171). In 1998, only 265 drums were
generated, and of these, less than 50% were
regulated as hazardous waste.
Alternatives for radioactive methods.
Chemiluminescent reagents have been success-
fully developed as alternatives to radioactive
materials in many research procedures (149)
Use of these alternatives has been encouraged
at NIH and other facilities. This has resulted
in signiﬁcant reductions in both procurement
and disposal of radioactive materials. 
Use of microscale techniques. Probably the
most profound changes in waste generation
that will occur in the near future will not
result from intentional pollution prevention
efforts; they will be a beneficial outcome of
changes in research technology. Knapp et al.
(217) referred to the paradigm shift that is
now occurring in experimental techniques. 
 108S6.  11/29/00 5:41 PM  Page 974    (Black plate)MINIMIZATION AND MANAGEMENT OF WASTES FROM BIOMEDICAL RESEARCH
In an analogous movement to that experi-
enced by information technology, minia-
turization and process integration are
being implemented to revolutionize the
way biochemical and chemical information
is acquired.
Process enhancements and automation
of research procedures are now rapidly
reducing the size of equipment and volumes
of reagents necessary to conduct sequencing,
assays, and other common laboratory proce-
dures. It may soon be possible to conduct
many, if not most, of the common research
procedures that once required liters of
reagents and the space of a full laboratory on
a microscopic scale. This has the potential to
greatly reduce the use of chemical reagents
and generation of hazardous wastes. For
example, the amount of material required
for experiments involved in the drug discov-
ery process will be reduced to 1/1000 of the
volumes currently required by the use of
these “laboratories on a chip” (218).
Recommendations 
The committee identiﬁed several areas where
action is needed to improve management of
wastes in research facilities.
Improve regulatory framework. Continue
efforts to reinvent the regulatory framework
governing waste minimization and manage-
ment with the goals of enhancing environ-
mental protection and eliminating regulations
that impose significant burdens on the
research mission without commensurate envi-
ronmental beneﬁts.
Expand training efforts. Incorporate sub-
ject matter pertaining to source reduction,
waste minimization, and management into
training programs for investigators, medical
students, health care providers, procurement
ofﬁcers, and facility support personnel.
Incorporate design elements for pollution
prevention into items used and developed by
research. Ensure that pollution prevention
and waste minimization objectives are consid-
ered in the research, design, development,
selection, and use of all reagents, supplies,
equipment, and procedures used in bio-
medical research. The same objectives should
be applied to the products of biomedical
research—all items used in the provision of
healthcare.
Establish an information clearinghouse.
Improve mechanisms for the transfer of cur-
rent information on waste minimization
and technology among all stakeholders—
investigators, facility support personnel,
regulatory agencies, and the public. The
Pollution Prevention and Energy Efficiency
Clearinghouse for Biomedical Research
Facilities (219) proposed by this conference
addresses this need.
Improve drug disposal. Give higher priority
to research on the potential public health and
environmental impacts of wastes containing
drugs and their residues and on methods to
mitigate these impacts.
Conclusion
The general conclusion reached by this com-
mittee responds to the primary concern raised
by the conveners of this conference: there is
no evidence to suggest that the anticipated
increases in biomedical research will signifi-
cantly increase generation of wastes or have
adverse impacts the general environment.
This conclusion assumes the positive, coun-
tervailing trends of enhanced pollution pre-
vention efforts by facilities and reductions in
waste generation resulting from improve-
ments in research methods will continue.
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